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Manganese-enhanced magnetic resonance imaging (MEMRI) opens the great opportunity 
to study complex paradigms of central nervous system (CNS) in freely behaving animals 
and reveals new pathophysiological information that might be otherwise difficult to gain. 
Due to advantageous chemical and biological properties of manganese (Mn
2+
), MEMRI 
has been successfully applied in the studies of several neurological diseases using 
translational animal models to assess comprehensive information about neuronal activity, 
morphology, neuronal tracts, and rate of axonal transport. Although previous studies 
highlight the potential of MEMRI for brain imaging, the limitations concerning the use of 
Mn
2+
 in living animals and applications of MEMRI in neuroscience research are in their 
infancy. Therefore, development of MEMRI methods for experimental studies remains 
essential for diagnostic findings, development of therapeutic as well as pharmacological 
intervention strategies.   
Our lab has been dedicating to develop novel MEMRI methods to study the 
pathophysiology underlying neurodegenerative diseases in murine models. In the first 
study, we investigated the cellular mechanism of MEMRI signal change during 
neuroinflammation in mice. The roles of neural cells (glia and neurons) in MEMRI signal 
enhancement were delineated, and ability of MEMRI to detect glial (astrocyte and 
XV 
 
microglia) and neuronal activation was demonstrated in mice treated with inflammatory 
inducing agents. In vitro work demonstrated that cytokine-induced glial activation 




and that glial Mn
2+
 content was not associated with 
glial activation. The in vivo work confirmed that MEMRI signal enhancement in the CNS 
is induced by astrocytic activation by stimulating neuronal Mn
2+
 uptake. In conclusion, 
our results supported the notion that MEMRI reflects neuronal excitotoxicity and 
impairment that can occur through a range of insults that include neuroinflammation.  
In the second study, we evaluated the efficacy of MEMRI in diagnosing the 
complexities of neuropathology in an ananimal model of a neurodegenerative disease, 
neuroAIDS. This study demonstrated that MEMRI reflects brain region specific HIV-1-
induced neuropathology in virus-infected NOD/scid-IL-2Rγc
null 
humanized mice. Altered 
MEMRI signal intensity was observed in affected brain regions. These included, but were 
not limited to, the hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, 
substantia nigra and cerebellum. MEMRI signal was coordinated with levels of HIV-1 
infection, neuroinflammation (astro- and micro- gliosis), and neuronal injury.  
Following the application of MEMRI to assess HIV-1 induced neuropathology in 
immune deficient mice humanized with lymphoid progenitor cells, our successful 
collaboration with Dr. Sajja BR (Department of Radiology, UNMC, Omaha, NE) led to 
the generation of a MEMRI-based NOD/scid-IL-2Rγc
null 
(NSG) mouse brain atlas. Mouse 
brain MRI atlases allow longitudinal quantitative analyses of neuroanatomical volumes 
and imaging metrics. As NSG mice allow human cell transplantation to study human 
disease, these animals are used to assess brain morphology. MEMRI provided sufficient 
contrast permitting 41 brain structures to be manually labeled on average brain of 19 
XVI 
 
mice using alignment algorithm. The developed atlas is now made available to 
researchers through Neuroimaging Informatics Tools and Resources Clearinghouse 
(NITRC) website   (https://www.nitrc.org/projects/memribrainatlas/).  
Finally, we evaluated the efficacy of N-acetylated-para-aminosalicylic acid 
(AcPAS) to accelerate Mn
2+
 elimination from rodent brain, enabling repeated use of 
MEMRI to follow the CNS longitudinally in weeks or months as well as inhibiting the 
confounding effects of residual Mn
2+
 from preceding administrations on imaging results. 
Two-week treatment with AcPAS (200 mg/kg/dose × 3 daily) accelerated the decline of 
Mn
2+
 induced enhancement in MRI. This study demonstrated that AcPAS could enhance 
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As being an excellent non-invasive tool with high spatial resolution and outstanding 
capacity for differentiating soft tissues to provide anatomical information of biological 
systems, magnetic resonance imaging (MRI) has become a pillar of radiological 
techniques in diagnostic imaging and has emerged as the major mode for assessing 
central nervous system (CNS) disorders [1]. MRI was introduced three decades ago into 
the clinical medicine [1]. Due to its properties, a variety of controls over image contrast, 
great flexibility and specificity in the detection of different pathophysiological 
mechanisms, metabolism assessment and anatomical as well as functional mapping, MRI 
has achieved widespread success not only in clinical, but also in research field [1-3]. 
Over the last 10 years, MRI utilization in experimental science has augmented [2][4,5]. 
Specially designed MRI units for experimental animals are now commercially available. 
Pictures of MRI units available for rodents at University of Nebraska Medical Center 
(UNMC) bio-imaging core facility are shown in figure 1.1. MRI acquisition softwares as 
well as post-processing tools are widely accessible [2]. Public and private financial 
sources have reinforced the expansion of MRI based brain atlases and databases [2]. 
In neuroscience research, innovations in diagnostic and therapeutic fields 
employing experimental animals rely on MRI.  Availability of MRI in clinical as well as 
preclinical settings permits direct linking of findings between humans and experimental 
animals [3]. This non-invasive imaging tool has been used in the studies involving animal 
models of  several neurological diseases, such as stroke, Parkinson’s disease, Alzheimer’s 
disease, and NeuroAIDS, epilepsy, brain tumors, multiple sclerosis, and other brain 
disorders [1-3,6-8].  
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Advances in MRI applications provide remarkable information about brain 
morphology, metabolism, physiology and function. The desire of obtaining more detailed 
information from brain, during normal and diseased conditions, with the help of MRI to 
improve our understanding is becoming more prominent.  Thus, the interest in the use of 
contrast agents is increasing. 
 
1.2. MRI contrast agents [1,9-13]  
MRI uses hydrogen atoms of water molecules to generate images. The primary 
contrast in MRI image mainly results from regional differences in intrinsic factors, T1 and 
T2, spin-lattice and spin-spin, relaxation times. Proton density (PD), which is also termed 
as spin density (SD) is another factor affecting image contrast. These factors are 
independently chosen to generate the tissue image contrast. The differentiation between 
healthy and diseased tissue depends upon their distinctive signal intensity that relies on 
tissue PD, T1 and T2 relaxation times. However, the signal intensity generated by these 
intrinsic contrast factors of healthy and diseased tissue frequently too limited to enable 
sensitive and specific diagnosis. Intrinsic relaxation times of healthy and diseased tissues 
frequently overlap, leading to compromised detection of abnormal tissue or function. 
This limitation can be overcome by using MRI contrast agents.    
Agents that affect the MRI signal contrast are paramagnetic (e.g. Mn
2+
, Gd), and 
superparamagnetic (e.g. iron oxide particles, such as Fe2O3, Fe3O4) and ferromagnetic 
(e.g. albumin coated magnetite). These agents help to increase sensitivity and specificity 
of MRI signal acquisition and provide substantial diagnostic information by reducing T1 
and T2 relaxation times of surrounding water protons in targeted tissue, leading to 
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generation of signal enhancement in shorter period of time and better signal-to-noise 
ratio. 
In biomedical research, most widely used contrast agents are paramagnetic and 
superparamagnetic. Depending upon the characteristics, such as chemical composition, 
molecular size, in vivo distribution, pharmacokinetic properties, and individual’s research 
question, agents are chosen for different studies. In our lab, we have used paramagnetic 
agent, Mn
2+
, to study neurodegenerative diseases that are modeled using rodents, due to 
its advantageous chemical and biological properties. 
 
1.3. Paramagnetic contrast agents 
Lauterbur et al. first suggested the use of paramagnetic ions as contrast agent for MRI in 
1978 [14]. Paramagnetic agents possess a permanent magnetic moment, which are 
randomly aligned in the absence of an externally applied magnetic field. When 
paramagnetic material senses externally applied magnetic field, the respective magnetic 
moments align parallel to the applied field.  Furthermore, aligned magnetic moments 
generate a local magnetic field, leading to an effective reduction in T1 (spin-lattice) and 
T2 (spin-spin), relaxation times of surrounding water protons of the targeted organ 
systems.  Reduction in the relaxation times results in MRI signal changes [1,9,10,12].  
Paramagnetic property of the material is based on the presence of number of 
unpaired electrons in atom. Most known subgroups of paramagnetic compounds are 
metal ions (e.g. Mn
2+
) and lanthanide elements (e.g. gadolinium (Gd)). The magnetic 
moment of unpaired electrons is greater than that of unpaired neutrons or protons. 
Therefore, agents with unpaired electrons are exclusively apt as MRI contrast agent 
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[9,10,12]. Even though, paramagnetic agents affect both T1 and T2 relaxation times, the 
shortening of T1 mainly causes an increase in signal intensity. The result of increase in 
signal intensity remains until the concentration of agent is reached to optimal level. Thus, 
use of paramagnetic material as a MRI contrast agent is advantageous, as it exhibits 




 – a paramagnetic contrast agent 
Mn
2+
, divalent ion, has paramagnetic properties. It
 
has 5 unpaired electrons and causes 
strong reduction of both T1 and T2 relaxation times of surrounding water protons of 
targeted tissue [6,13,15,16]. The magnitude of T1 or T2 relaxation time reduction depends 
on the local Mn
2+
 concentration. It can be described by following equation [13]:  




Rio = 1/Ti (i=1,2) is the observed relaxation rate 
[Mn
2+
] = the concentration of the Mn
2+
 ion  
Ri = the relaxivity constant, and  
Rt(0) = the relaxation rate of the solvent without manganese ([Mn
2+
] = 0)  




a divalent ion, and its unique properties as a MRI contrast agent is 
known as Mn
2+
-enhanced magnetic resonance imaging (MEMRI). 
 
1.5. MEMRI 
The investigation of Mn
2+
 as contrast agent coincides with early days of nuclear magnetic 
resonance (NMR) [4,6,17]. Initial findings with the help of Mn
2+
 played important role in 
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understanding of water-exchange effects, which was a crucial step in the development of 
T1 shortening contrast agents [4,6,18,19], and quantitative structural information of 
biological systems, which helped to develop techniques to confirm three-dimensional 
protein structure using NMR [4,20].   Mn
2+
 has been present since the beginning of MRI. 
Lauterbur et al. with the help of Mn
2+
 showed that relaxation times could affect signal 
intensity. Over 25 years ago, the use of Mn
2+
 as a MRI contrast agent was initialized.  
London et al. studied toxic effects of Mn
2+
 on anesthetized rats [21]. Since then, the use 
of MEMRI in experimental neuroscience for imaging the rodent brain has significantly 
evolved [4]. Our observation about MEMRI use in neuroscience research over the last 10 
years is showed in figure 1.2.a and 1.2.b. Paramagnetic property of Mn
2+
 causes an 
effective reduction of the T1 (spin-lattice) relaxation times of the surrounding water 
protons of the targeted organs, leading to signal enhancement. Positive contrast signal 
enhancement is detected on T1-weighted images of tissues in which Mn
2+
 accumulates 
[4,6,9,12,15,16,22]. The difference between 3-D MRI image of brain of a mouse which 
was injected with MnCl2 and 3-D MRI image of a brain of a mouse injected with saline 
showed in figure 1.3. Mn
2+
-based contrast enhancement and neuroarchitecture details are 
clearly visible in these mice. Yet, one major weakness of Mn
2+
 is associated cellular 
toxicity upon overexposure [4-6,12,15,16,23]. However, Mn
2+
 is considered as least toxic 
among the essential trace elements. This divalent ion is also an essential trace element, as 
the lack of it leads to severe disorders in humans [5,6,16,24].  
Interpretation of MEMRI findings requires profound knowledge of Mn
2+
 behavior 
in biological systems under healthy and diseased conditions as well as of experimental 





entrance in the CNS, main applications of MEMRI in biological systems, methodological 
considerations of Mn
2+
administration in animals, Mn
2+
 toxicity, MEMRI in humans, and 
objective and related study aims of my Ph.D. thesis.  
 
1.6. Properties of Mn
2+
 in the CNS 
Mn
2+ 
is recognized by biological systems as a chemical analogue of calcium (Ca
2+
), same 
charge and similar ionic radii (Mn
2+
 = 89 pm and Ca
2+
 = 114 pm) [6].  Therefore, Mn
2+
 
can enter into the neurons and other excitable cells through voltage-gated calcium 
channels (L-type voltage-gated Ca
2+









antiporter [4-6,12,15,25-30]. Once inside the cells, it binds with high 
affinity to proteins and nucleic acids. Inside the neuronal cells, Mn
2+ 
accumulates in the 
endoplasmic reticulum (ER), is packaged into the vesicles and is transported along the 
axons anterogradely [5,6,25,27,31]. Upon reaching the pre-synaptic membranes it is 
released at the synaptic cleft and taken up by the adjacent neurons [4-6,15,25,27]. 
Scheme of Mn
2+
 transport mechanism between neurons in CNS is depicted in figure 1.4. 
Systemic administration of Mn
2+
 leads to its accumulation in all tissues, 
significantly detected in liver, kidney, heart and brain [6,16,32,33]. As major route of 
entry for Mn
2+
 into the CNS is through CSF-Blood barrier, the time course, uptake and 
distribution of Mn
2+
 varies across the brain regions [6,15,16]. Initial Mn
2+
 accumulation 
occurs in the brain regions near to ventricles and then gets distributed throughout the 
entire brain. Contrast enhancement in CNS reaches to its equilibrium 24 hours after 
MnCl2 administration (Figure 1.5) [6,15,16,32,34,35]. It has been shown that Mn
2+ 
has 





has long half-life in the brain, 51–74 days in rodents [16,36] and more 
than 100 days [6,37] in monkeys, whereas short half-life in visceral organs like liver and 
heart, which might indicate that Mn
2+
 is carrier-transported into the brain, but not out of it 
[6,16,36]. Efflux of Mn
2+
 from brain is not well studied but is believed that the efflux 
mechanism is diffusion mediated [6,38]. 
 
1.7. Entry of Mn
2+
 into the CNS  
Mn
2+
 enters into the brain via the following three major routes [4-6,12,15,16]. 
After systemic administration of MnCl2, Mn
2+
 enters the brain through two different 
routes as follows: 
1) Through choroid plexus via CSF (major and rapid entry route) 
2) Through BBB by diffusion or active transport processes (minor entry route) 
At physiological plasma Mn
2+
 concentration, it is mainly transported across the 
endothelial cells of brain capillaries, and after bolus systemic injection of Mn
2+
 (at high 
concentration), the major route of entry is via choroid plexus. 
Application of Mn
2+
 via the olfactory system provides the easiest route for Mn
2+
 
entrance into the brain, as olfactory tract is not protected by the BBB or other barriers. It 
has been shown in rodents that upon exposure to air containing Mn
2+
, it is able to enter 
into the olfactory bulb via the olfactory epithelium.  




- an intracellular contrast agent 
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Two essential factors have been derived from the results obtained with the help of Mn
2+ 
[16,22].  
1) Signal received after MnCl2 administration comes from the intracellular Mn
2+
, 
whereas another popular paramagnetic MRI contrast agent, chelated 
gadolinium, remains extracellular. Therefore, MEMRI has been useful to map 
signal intensities according to cellular density of the targeted tissue, and thus to 
visualize brain cytoarchitecture. 
2) Rate of Mn
2+
 uptake is useful to detect normal and affected tissue functions. 
Normal uptake defines the normal function of the tissue. Therefore, disruption 
of Mn
2+
 uptake serves as a biomarker to detect the pathological conditions such 
as stroke, neuroAIDS, epilepsy, etc. 
 
1.9. Applications of MEMRI in experimental neuroscience  
Depending upon above mentioned properties of Mn
2+
, literature has divided the 
applications of MEMRI as a research tool in three major groups [5,6,15,16,22]. But, here, 
I have divided the applications in four major groups.  
1) Measurement of neuronal activity (functional assessment); this application of 
MEMRI is termed as activation-induced MEMRI (AIM-MRI) [29]; figure 1.6  
2) Assessment of anatomical/morphological details [6]; figure 1.3 
3) Assessment of neuronal tracts and assessment of axonal connectivities [6]; figure 
1.7  
4) Assessment of rate of axonal transport [5]  
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Taking advantage of these applications, researchers have been using MEMRI in 
neurosciences to address problems using translational models of brain diseases.  
 
1.10. Methodological considerations for Mn
2+
 administration 
1.10.1 Preparation of MnCl2 solution:  
The most common and easy way to deliver Mn
2+ 
to the experimental animals is through 





. The salt material (MnCl2) is commercially available in three different 
grades in major biochemical companies, for example:  
1) MnCl2, powder form, anhydrous, purified (> 99%), molecular weight (M.W.)- 125.84 
g/mol (Sigma-Aldrich, St Louis, MO)  
2) MnCl2·4H2O, flake form, hydrous, highly purified (99.99%), M.W.- 197.91 g/mol 
(Sigma-Aldrich, St Louis, MO) 
3) MnCl2 solution, prepared in 18 megohm water, 1.00 ± 0.001 M (Sigma-Aldrich, St 
Louis, MO) 
All three forms are suitable for experimental purpose. We have used MnCl2·4H2O for all 
the studies carried out in our laboratory and for studies mentioned in my dissertation.  
Chemical and physical properties, especially osmolarity and pH, of the MnCl2 
solution to be used for experimental purpose need to be considered for successful 
application [6,15,16]. Osmolarity of body fluid is around 300 mOsm/l. One has to make 
sure that administered amount of MnCl2 will not affect the natural osmolarity by using 
the isotonic solution of MnCl2, 100 mM. Solutions with significant lower osmolarity 
(<100mM) are hypotonic, and solutions with significant higher osmorality (>100 mM) 
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are hypertonic. This parameter has strong impact when MnCl2 solution is injected 
directly into the brain tissue (stereotaxic injection), but has very minor consequences 
when injected systemically, including intravenous (IV), intraperitoneal (IP), 
subcutaneous (SC). For all of our studies, MnCl2 has been administered systemically, 
especially through intraperitoneal route [25,39,40]. Therefore, we have been successfully 
using the MnCl2 solution with lower concentration (50 mM). 
Another important property to consider while preparing the MnCl2 solution is pH. 
It is essential to adjust the pH of the solution at 7.4 for effective application. The 
procedure used to prepare MnCl2 solution for our studies is described in materials and 
methods section of respective chapters.  
 
1.10.2. Administration of Mn
2+
  
Due to acute and chronic cellular toxicity of Mn
2+
, one has to take into consideration of 
experimental methodology, including delivery route, appropriate dose, osmolarity as well 
as pH of MnCl2 solution to deliver adequate amount of Mn
2+
 to the site of interest in a 
time efficient manner to receive desired contrast signal while avoiding any toxic effects 
of Mn
2+ 
to experimental animals and its interference with normal physiological 
properties.  
It has been showed that systemic administration of MnCl2 solution in a 
fractionated manner (i.e. smaller doses, multiple injections) is beneficial to reach 
sufficient Mn
2+
 accumulation into tissues (especially brain) to obtain high contrast signal 
while minimizing toxic side effects [23,41]. We used fractionated administration scheme 
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for all of our studies [25,39,40]. Below, I have summarized commonly used 
administration routes for MnCl2 solution in the literature. 
In order to increase the efficiency of MEMRI, the delivery route is chosen based 
on the application [4,5,13,15,16]. MEMRI applications are described under the heading 
applications of MEMRI in experimental neuroscience in the current chapter. In general, 
MnCl2 can be injected intraperitoneally (IP), intravenously (IV), subcutaneously (SC), 
intracranially (stereotaxic injection) into the area of interest, and can be delivered by 
using commercially available osmotic pumps. Among systemic administration routes (IP, 
SC, IV), there is no strong evidence suggesting that one route is better than others or that 
one route causes lesser toxicity compared to others.  
Kuo et al. measured relative T1 relaxation times in mice (C57Bl/6) brains with 
different modes of systemic administration (IP, IV, SC). Authors concluded that all the 
systemic routes of administration showed significant reduction in T1 values following 
MnCl2 infusion and both the temporal and regional changes in cerebral T1 relaxation 
times are relatively independent of the route of administration [42].  
Few studies have used osmotic pumps to deliver Mn
2+ 
into the experimental 
animals [13,43,44]. Osmotic pumps deliver a specific concentration of Mn
2+
 over a 
specified period of time.  It has been proposed that slow release of Mn
2+
 can decrease 
associated toxicity issues. Currently, ALZET® osmotic pumps company (Durect 
Corporation, CA) sales pumps in the market. Company describes that ALZET pumps 
operate on osmotic pressure difference between the tissue environment (in which the 
pump is implanted) and a compartment within the pump. When water enters into the 
pump compartment from the surrounding tissue, it compresses the flexible reservoir, 
13 
 
leading to displace MnCl2 solution from the reservoir at a controlled rate to the 
surrounding body environment of the animal. ALZET provides a variety of delivery rates, 




 - a trace element and related toxicity 
Mn
2+ 
is an essential heavy metal for cellular processes and normal development. It plays 
essential role in the regulation of metabolism, cell energy, immune response, blood sugar 
homeostasis, blood clotting, reproduction, digestion, skeletal system development, bone 
growth as well as in synaptic function as an antioxidant and enzymatic cofactor in the 
brain [5,6,45,46]. It serves as a significant co-factor for enzymes such as glutamine 
synthetase, pyruvate carboxylase, arginase, phosphoenolpyruvate carboxykinase and 
mitochondrial superoxide dismutase [5,6,46,47]. In humans, deficiencies in Mn
2+ 
are 
associated with skin lesions, epileptic seizures, bone malformation, increased Ca
2+
 and 
phosphorous levels, among others [5,16]. Mn
2+ 
is generally excreted through the 
hepatobiliary route [6,47,48]. However, in excess, Mn
2+ 
is toxic [4-6,15,16,47]. Acute 
overexposure to this ion happens when administered systemically to patients, leading to 
cardiac toxicity, renal failure, liver toxicity, and may be death [6,16]. Moreover, chronic 
exposure to Mn
2+ 
is neurotoxic, a brain disorder characterized by neurological and 
psychological disorders, a progressive neurodegenerative disorder, called as 
‘Manganism’, accompanied by loss of Dopaminergic neurons [5,16]. In this disorder, 
Mn
2+ 
is highly concentrated in basal ganglia. Symptoms of manganism are similar to 
symptoms of Parkinson’s disease, such as tremors, widespread rigidity, hallucination, 
bradykinesia, sleep disorder, lack of facial expressions, slurred speech and memory loss 
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[15,49]. It was observed that excessive exposure of this heavy metal damages the CNS by 
a number of mechanisms, including inhibition of mitochondrial oxidative 
phosphorylation, which leads to reduced ATP [49,50], impaired astrocyte-neuronal 
interactions, indirect effect on excitatory and inhibitory influences [47]. Aberrant Mn
2+
 
accumulation in brain has also been linked to Huntington’s disease and other neurological 
disorders [49]. Normal human brain Mn
2+
 concentration is at 5.32-14.03 ng Mn
2+
/mg 
protein, which is equivalent to 20-52.8 µM Mn
2+ 
(around 1.1-2.9 ppm). General toxic 
responses occur when Mn
2+
 concentration is elevated to around 3 fold (i.e. 15.96-42.09 
ng Mn
2+
/mg protein or 60.1-158.4 µM Mn
2+
) [49]. 
The most common method to administer Mn
2+ 
to experimental animals is through 
the injection of MnCl2 solution. Detailed information about MnCl2 solution and 
administration routes are discussed under the heading preparation of MnCl2 solution and 
administration on Mn
2+
 in the current chapter. This paragraph discusses toxicity related to 
MnCl2.  According to the Material Safety Data Sheet (MSDS) [16], MnCl2 is a harmful 
chemical agent, which causes eye and skin irritation upon contact. Target organs include 
the CNS and the lungs. As per the MSMDS report, following characteristic signs and 
symptoms of exposure have been identified: ‘Men exposed to manganese dusts showed a 
decrease in fertility. Chronic exposure primarily affects CNS, and early symptoms are 
languor, sleepiness and weakness in the legs.’ In more advanced cases, emotional 
disturbances such as uncontrollable laughter and a spastic gait with tendency to fall while 
walking. Mn
2+ 
is also known to be a potential mutagen, and pneumonia is highly 
observed in the workers exposed to dust of Mn
2+ 
compounds. Therefore, one must wear 
appropriate barriers and take proper precautions while interacting with MnCl2 material 
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for experimental purposes. LD50 toxicity data reports in the MSDS for MnCl2 are shown 
in Table 1 [16]. 
Indeed, acute and chronic cellular toxicity of Mn
2+
 repressed its transformation as 
clinical MRI contrast agent.  Regardless of these toxicity issues, to take the advantage of 
chemical and biological properties of Mn
2+
 as a contrast agent, researchers generated 
alternative ways to avoid toxicity of Mn
2+
 while delivering sufficient amount of Mn
2+
 to 
the site of interest in an efficient manner in experimental animals.   
For all of our studies, level of Mn
2+
 used is below the neurotoxic levels. Animals 
were observed daily after each i.p. MnCl2 injection and 24 hours after the injection to 
detect Mn
2+
 toxicity. If tremor or convulsion (signs of Mn
2+
 overdose) persisted longer 
than 3 minutes or lethargy (decreased locomotion), and loss in body weight was observed 
at 24 hours, mice were euthanized [25]. Moreover, it is demonstrated that concentration 
of Mn
2+ 
> 200 µM can affect the neuronal activity [51]. We measured the R1 values to 
determine absolute Mn
2+
 concentration before and after Mn
2+
 administration in cortex 
region of mice (n=11). There was ~ Δ 0.15 alteration in R1 values after Mn
2+
 
administration. R1 values were less than 0.70 after Mn
2+
 administration (Figure 1.8). 
These R1 values then were compared with previously reported correlation between R1 
values and relative Mn
2+
 concentration. This comparison corresponded to less than 40 
µM Mn
2+ 
in the brain parenchyma region of experimental animal used in our studies 
(Figure 1.8). Thus, with the help of behavioral observation and measured R1 values, we 
confirmed that our fractionated administration scheme for MnCl2 is non-toxic to animals 
and injected Mn
2+




1.12. MEMRI in Humans 
Even though the use of Mn
2+ 
as a MRI contrast agent in clinical settings has been 
restricted due to cellular toxicity, properties of Mn
2+
 such as high sensitivity and 
specificity, and its prominent results in rodent, song birds, and monkeys, encouraged 
researchers to develop chelates of Mn
2+
 for the clinical use. Several chelates were 
developed and few of them were introduced into the market by biochemical companies. 
Manganese dipyridoxaldiphosphate (MnDPDP) was the first Mn
2+
-based contrast agent 
approved by FDA. This product was approved for the liver imaging [5,6,9,16,52,53]. 
Product containing Manganese dipyridoxaldiphosphate (MnDPDP) was introduced into 
the market by GE healthcare called Teslascan®. MnDPDP is anionic chelate and 
dissociates quickly after administration to yield free Mn
2+
 ions. Although MnDPDP was 
mainly considered for liver imaging, some studies demonstrated its usefulness in imaging 
of pancreas and biliary tract [9]. Another pharma-company, Eagle Vision Pharmaceutical, 
is testing contrast agent called SeeMore® for cardiac imaging [5]. This product consists 
free Mn
2+
 ions formulated along with Ca
2+





 inhibitor. This agent is currently used in dogs and pigs for cardiac and vascular 
imaging. Few promising chelating agents were invented for clinical use, however, further 
research needed for successful translation of MEMRI. 
MEMRI has been successfully used in previous studies to study brain disorders in 
experimental animals. Although previous studies highlight the potential of MEMRI for 
brain imaging, the limitations and boundaries concerning the use of Mn
2+
 in living 
animals and development of new MEMRI applications in neuroscience are at the 
beginning level. Therefore, during the course of my Ph.D, we have determined the 
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cellular source for altered signal intensity during pathological conditions, evaluated the 
efficacy of chemical compound for washing out the Mn
2+
 from the rodent brain for 
longitudinal studies, and developed tools such as 3-D mouse brain atlas, which is now 
available for public use at NIRTC resources.  
 
1.13. Objective and aims of the thesis 
1.13.1. Objective  
To develop manganese-enhanced magnetic resonance imaging (MEMRI) methods to 
study pathophysiology underlying neurodegenerative diseases in murine models. 
 
1.13.2. Aims 
1) Investigate role of glia and neurons in manganese-enhanced magnetic resonance 
imaging (MEMRI) signal enhancement during inflammation (Chapter 2). 
 
2) Evaluate the application of MEMRI in diagnosing the brain pathology in animal 
models of neurodegenerative diseases (Chapter 3).  
 
3) Generate MEMRI-based NOD/scid-IL-2Rγc
null
 mouse brain atlas (Chapter 4). 
 
4) Evaluate the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate 
Mn
2+






Figure 1.1. MRI units for small animals at UNMC bio-imaging core facility. Both 


































Figure 1.2. MEMRI in experimental neuroscience. Distribution of MEMRI publications 


































Figure 1.4. Scheme of Mn
2+
 transport mechanism in CNS. (a) Once Mn
2+
 entered the 
CNS, it enters the neurons through voltage gated Ca
2+
 channels. (b) Inside neurons, ions 
are accumulated in the endoplasmic reticulum and packaged into vesicles. (c) Mn
2+
 ions 
are further transported anterogradely along the axons with the help of microtubule 
assembly. (d and e) Upon reaching to the presynaptic terminal, Mn
2+
 ions get released at 
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Figure 1.5. Temporal Mn
2+
 distribution across the brain. (Top) Coronal, (middle) sagittal 
and (bottom) axial MEMRI sections of a mouse brain in vivo 2, 8, and 24 h after 
intraperitoneal injection of 320 μmol/kg MnCl2 (9.4 T, 100 μm isotropic resolution). Cb, 
cerebellum; cp, choroid plexus; CSF, cerebrospinal fluid; dg, dental gyrus; fr, fasciculus 
retroflexus; gp, globus pallidus; ha, habenula; ic, inferior colliculus; ipn, interpeduncular 
nucleus; lh, lateral habenula; ls, lateral septum; ob, olfactory bulb; pi, pituitary gland; pv, 







Figure 1.6. MEMRI measures neuronal activity. (a) MEMRI of acute cocaine-induced 
brain activation. Activation maps are superimposed onto T2-weighted MRI with 
corresponding rat brain atlas sections shown on the right. Activated voxels are clustered 
in the hemisphere with the BBB disrupted by hyperosmolar mannitol. The contralateral 
hemisphere had an intact BBB and did not show activation. Activated structures include 
olfactory cortex; medial, ventral, and lateral orbital cortex; pre-limbic cortex; cingulate 
cortex; nucleus accumbens (NAc), caudate putamen; ventral pallidus; external globus 
pallidus; agranular insular cortex; thalamus; hypothalamus; retrosplenial dysgranular 
cortex; hippocampus; and primary and secondary somatosensory and motor cortex. (b) 
Averaged MEMRI response time course in the NAc from animals receiving saline (n = 6) 
and 0.5 mg/kg (n = 5) and 2.0 mg/kg (n = 6) cocaine. All time courses were normalized 
to the baseline signal after bolus injection of mannitol, but before the injection of cocaine 









Figure 1.7. MEMRI detects neuronal tracts. (a, b) Horizontal and (c) axial MEMRI 
sections and (d) 3D volume rendering of a mouse optical system in vivo 24 h after 
intravitrial administration of 0.06 μmol MnCl2 (2.35 T, 117 μm isotropic resolution). lgn, 
lateral geniculate nucleus; och, optic chiasm; on, optic nerve; ot, optic tract; sc, superior 












Figure 1.8. Measurement of R1 values. (a) R1 (1/T1) values were measured in mice brain 
cortex before and after Mn
2+
 injections. Mice were injected with our lab optimized 
fractionated MnCl2 injections. (n=11). (b) R1 values plotted against MnCl2 concentration, 
significant linear correlation was observed between the two (n = 4 MRI acquisitions, P < 














Table 1.1. LD50 (toxicity) data for MnCl2.  
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CHAPTER - 2 
Role of Glia and Neurons in Manganese-Enhanced Magnetic 
















) is a potent magnetic resonance imaging (MRI) contrast agent used to 
improve anatomical visibility, most notably, neural structures. Unlike other agents, such 
as gadolinium, iron oxide, iron platinum and protein-based compounds, Mn
2+
 remains at 
a very early stage in clinical development, based in large measure to its inherent 
neurotoxicity [1-3]. Nonetheless, a number of recent reports demonstrate that Mn
2+
-
enhanced MRI (MEMRI) in normal animal brains provide novel information relevant to 
anatomical, integrative, and functional assessments of neuronal connectivity. These 
findings are linked to the abilities of Mn
2+
 ions to efficiently enter neurons through 
voltage-gated calcium channels [4-7]. 
A major drawback for the use of Mn
2+
 as a contrast agent in studies of human 
disease models rests in understanding its cellular mechanism and profiles [8,9]. Despite 
such potential limitations, significant attempts have been made, in recent years, to use 
MEMRI in studies of the pathobiology of neurodegenerative diseases utilizing relevant 
animal models [9-25]. Nonetheless and paramount to the successful  application of 
MEMRI is not simply  the ability to deliver Mn
2+
 to the  site  of interest or of disease but 
in determining the cell types and cellular mechanisms that engage the ion and produce the 
signal enhancement observed. Based on our long standing interest in the links between 
neuroimmunity and neurodegenerative diseases we reasoned that pathological activation 
of the immune-competent glial cells could represent an obligatory event for any MEMRI 
signal enhancements. In support of this idea is a wealth of prior studies demonstrating 
that MEMRI signal enhancements were co-localized with reactive glia [14,22,26,27].  
Reproduced with permission from Bade AN, Zhou B, Epstein AA, Gorantla S, Poluektova LY, Luo J, 
Gendelman HE,  Boska MD, Liu Y; Improved Visualization of Neuronal Injury Following Glial Activation 
by Manganese Enhanced MRI; J Neuroimmune Pharmacol. 2013, Sep; Copyright Springer 
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However, it was never clear if such signal enhancements resulted from Mn
2+
 
accumulation in the glial cells directly, or from elevated manganese uptake by neuronal 
cells stimulated by glial reaction.  
Thus, we sought to better elucidate the cellular basis of MEMRI signal in studies 
of neurodegenerative diseases. We reasoned that if the cell association of the signal 
enhancement is determined, MEMRI can be developed as a potential imaging tool to 
monitor real-time glial-neuronal interactions. To this end, we investigated relationships 
between microglial and astrocytic activation linked to Mn
2+
 uptake. These studies were 
both in vitro as performed in glial and neuronal cells and in vivo using MRI following 
lipopolysaccharide (LPS) treatments in mice. The results showed that astrocytic reactions 
result in MEMRI signal enhancement by stimulating neuronal Mn
2+
 ion uptake. 
 
2.2. Materials and Methods 
2.2.1. PC-12 Differentiation 
A rat adrenal pheochromocytoma-derived cell line - PC-12 Tet-Off, was used to study 
neuronal Mn
2+
 uptake. PC-12 cells were utilized here because they serve as a relevant in 
vitro model system for primary neuronal cells [28,29]. They have been widely used to 
study voltage-gated Ca
2+
 channels [30,31] and effects of Mn
2+
 exposure on these cells 
[2,32,33]. Following withdrawal of doxycycline (Dox) from the medium, PC-12 cells 
were differentiated with nerve growth factor (NGF, R&D Systems 1156-NG/CF).  
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2.2.3. Cell Co-culture and Activation  
 
Figure 2.1. PC-12 cells (differentiated to neurons) were co-cultured with primary 




Primary cultured mouse astrocytes and microglia were prepared from NOD-scid IL2Rg
null
 
(NSG) newborn pups as described in [34,35]. Differentiated PC-12 cells were de-attached 
and seeded in multi-well plates. Primary astrocytes and microglia were placed on inserts 
and co-cultured with PC-12 cells respectively at the cell ratio of 1:1 (10
5
 cells, Fig. 2.1). 
The co-cultured cells were then treated with a combination of cytokines including 
interferon gamma (IFN-) and tumor necrosis factor alpha (TNF-) at the following 
concentrations: 25 (IFN-) and 2.5 (TNF-), 50 and 5.0, or 100 and 10.0 ng/ml to induce 
glial activation. After nine hours of treatment, MnCl2 solution was administered in the 
medium at concentrations of 80, 160 and 320 M. An untreated cell group was used for 
control measurements. Cells were washed and resuspended at 2 and 15 hours after MnCl2 
treatment. Inductively coupled plasma mass spectrometry (ICP/MS) was used to measure 
the Mn
2+
 concentration. Experiments were performed with triplicate samples.  
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2.2.4. Mouse Model of Acute Neuroinflammation 
All animal procedures performed in this study were approved by the University of 
Nebraska Medical Center Institutional Animal Care and Use Committee. LPS was 
intracranially (i.c.) injected to induce focal inflammation in male wild-type C57BL/6 
mice (n = 13, 6-8 weeks old). Using a stereotactic injection device, 10 µg (LPS) in 2 µl 
PBS was administrated into the left hemispheric caudoputamen (coordinates from 
bregma: 3.0 mm lateral, 0.5 mm anterior, and −3.5 mm ventral). The LPS solution was 
delivered with a 27 g needle at the flow rate of 0.2 µl per minute. A sham-operated 
control group (n = 11) was injected with 2 µl PBS through the i.c. route with the same 
parameters as the LPS group.  
 
2.2.5. MEMRI 
MnCl2 (50 mM) was administrated i.p. with the dose of 60 mg/kg consecutively four 
times at 24 hour intervals before MRI. Another group of mice (n = 10) with i.c. LPS 
injection was added to study the effect of LPS alone on MRI signal enhancement. This 
group was administrated with saline through the i.p. route with the volume of 6 ml/kg at 
the same times as the MnCl2 injection. The LPS mice injected with MnCl2 are designated 
as LPS + MnCl2 hereafter, and the LPS mice injected with saline are designated as LPS + 
saline. The sham-operated mice with i.c. PBS injection are designated as PBS + MnCl2. 
One day after LPS or PBS injection, six LPS + MnCl2 mice, five LPS + saline mice and 
five PBS + MnCl2 mice were scanned using MRI. The remaining mice were scanned 
seven days after LPS or PBS injection. After MRI, the mice were euthanized and brains 
were removed for histology. 
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MRI was performed 24 hours after the last MnCl2 injection on a 7T/21 cm 
horizontal bore scanner (Bruker, Billerica, MA) operating ParaVision 5.1 with a volume 
coil for RF transmission and a 4-channel phased-array coil for signal reception. Mice 
were scanned using T1 mapping (fast spin echo with variable TR from 0.4 s to 10 s, 12 
slices, slice thickness = 0.5 mm, in-plane resolution = 0.1x0.1 mm
2
) and T1-wt MRI 
(gradient recalled echo, TR = 20 ms, flip angle = 20
o




To reduce the influence of the inhomogeneous signal reception by the surface 
coil, N3 field inhomogeneity correction [36] was first performed on each image using 
MIPAV (CIT, NIH). The brain was then manually aligned to the LONI atlas (LONI, 
UCLA) in Analyze (AnalyzeDirect, KS). The alignment is necessary for accurate 
quantification of signal enhancement due to manganese uptake. 
MRI signal enhancement was measured on a slice-by-slice basis in the axial 
direction. On each slice, the injection site was first identified. The mean value and 
standard deviation (SD) of the signal intensity about the corresponding location of the 
needle hole on the contralateral hemisphere was measured (in a larger ROI), then the 
intensity threshold was defined as the mean value plus 2 SDs. This threshold was applied 
on the ipsilateral hemisphere as the lower boundary to identify enhanced area about the 
needle hole. The enhanced volume was the summation of the enhanced areas multiplied 
by the slice thickness. The total enhanced volume was then normalized to the needle 
depth. The signal enhancement ratio was calculated by dividing the mean signal intensity 




Mice were euthanized immediately after MRI. Brains were collected and fixed in 4% 
paraformaldehyde overnight and embedded in paraffin. The paraffin blocks were cut into 
5 μm thick sections. These brain tissue sections were then labeled with rabbit polyclonal 
antibodies for glial fibrillary acidic protein (GFAP) (1:1000, Dako, Carpinteria, CA). 
Microglia were stained with rabbit polyclonal antibodies for ionized calcium binding 
adaptor molecule 1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA). The polymer-
based HRP-conjugated anti-mouse and anti-rabbit Dako EnVision systems were used as 
secondary detection reagents and 3,3’-diaminbenzidine (DAB, Dako) used as a 
chromogen. All paraffin-embedded sections were counterstained with Mayer's 
hematoxylin. Images were captured with a 10x objective using Nuance EX multispectral 
imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and 
image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company, 
Hopkinton, MA) was used for quantification of GFAP and Iba-1 expression in the region 
of interest (in and around the injection line) as reflected by intensity/µm
2
. Area-weighted 
average intensity was calculated for GFAP and Iba-1 expression by dividing the total 
signal intensity, for each partitioned area, by area (µm
2
).  
For immunofluorescence labeling, brain sections about the injection line were 
treated with the paired combination of primary antibodies mouse anti-synaptophysin 
(SYN) (1:1000, EMD Millipore), and rabbit anti-microtubule-associated protein 2 
(MAP2) (1:750, EMD Millipore). Primary antibodies were labeled with secondary anti-
mouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor 488 
and Alexa Fluor 594, and nuclei were labeled with DAPI (4,6-diamidino-2-
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phenylindole). Slides were coverslipped with ProLong Gold anti-fade reagent 
(Invitrogen, Carlsbad, CA). Then slides were stored at −20°C after drying for 24 hours at 
room temperature. Images were captured at wavelengths encompassing the emission 
spectra of the probes, with a 10X objective by Nuance EX multispectral imaging system 
fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and image analysis 
software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) used for 
quantification. For SYN and MAP2 expression, area-weighted average fluorescence 
intensity was calculated in the region of interest (in and around the injection line) by 







2.2.7. Statistical Analysis 
T-test was used to compare the cell manganese concentrations in the in vitro study. 
Correlation between manganese uptake by PC-12/glial cells and cytokine level were 
performed using Pearson’s correlation coefficient calculation. In the in vivo MEMRI 
study, t-test was used to compare all the variables in between LPS and PBS injected 
groups, whereas Pearson’s correlation coefficient was used to test for correlations between 





 Uptake by PC-12 Cells 
The manganese concentration in PC-12 cells co-cultured with astrocytes and microglia 
was shown in Fig. 2.2.a and 2.2.b, respectively. Mn
2+
 concentration in PC-12 cells was 
plotted against cytokine level (IFN-/TNF-α, ng/ml) at 2 and 15 hours of MnCl2 
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incubation time (left and right plots, respectively). In this figure, several properties of the 
baseline manganese uptake by PC-12 cells (when IFN-/TNF-α = 0/0) are manifest. First 
of all, the measurements at MnCl2 concentration = 0 shown in Fig. 2.2 by dash-dot lines 
demonstrated that PC-12 cells endogenous manganese was low, suggesting the 
manganese in PC-12 must be taken from the extrinsic source – the MnCl2 solution. 
Secondly, the manganese uptake by PC-12 cells depends on the availability of the 
extrinsic manganese (i.e., the concentration of MnCl2 solution). It can be seen that the 
PC-12 manganese concentration is positively correlated with MnCl2 concentration in all 
the plots in Fig. 2.2 (Pearson’s correlation, r ≥ 0.900, p < 0.05). The incubation time of 
MnCl2 apparently plays a role in PC-12 manganese uptake as well. The manganese 
concentration in PC-12 cells at 15 hours was much higher than at 2 hours, evidenced by 
comparing the left and right columns in Fig. 2.2 (p < 0.05 at MnCl2 = 160 and 320 µM). 
These observations were in agreement with previous findings [3]. 
The role of glial reaction on PC-12 manganese uptake involves a number of 
factors including the glial cell type, and the level and time of glial reaction. Fig. 2.2.a 
illustrates that the change in PC-12 manganese uptake resulted from astrocytic activation. 
At short inflammatory cytokine treatment time (2 hours), PC-12 manganese uptake was 
almost linearly increased with cytokine levels at 160 µM (Pearson’s correlation, r = 
0.990, p < 0.01) and 320 µM (Pearson’s correlation, r = 0.998, p < 0.01). Prolonged 
treatment (15 hours) seemed to suppress the manganese uptake by PC-12 cells with 
cytokine levels at 160 and 320 µM MnCl2. However the negative correlation between the 
manganese concentration and cytokine level was not significant (p = 0.064 at 160 µM, p 
= 0.052 at 320 µM). 
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On the other hand, microglial reaction had no significant impact on PC-12 
manganese uptake. At the high MnCl2 concentration (320 µM) and short treatment time 
(2 hours), it showed the trend of negative impact (Pearson’s correlation, r = -0.935, p = 
0.065). The PC-12 manganese uptake remained constant at all other MnCl2 
concentrations at both 2 and 15 hours.  
It was interesting to see that at 15 hours Mn
2+
 uptake by PC-12 cells co-cultured 
with astrocytes at baseline (IFN-γ/TNF-α = 0/0) was twice the concentration of Mn
2+
 as 
PC-12 cells co-cultured with microglia. This result could be due to increase in Mn
2+
 
efflux from astrocytes in response to high extracellular Mn
2+
 [37], which could cause 
increase in extracellular Mn
2+ 
concentration, and thus lead to more Mn
2+
 uptake by PC-12 
cells. 
 
2.3.2. Manganese Uptake by Glial Cells 
No significant exogenous manganese uptake by glial cells was observed in this study at 
any extracellular MnCl2 concentration, glial activation level, or times of exposure (data 
not shown). The ICP/MS measurements showed that the intrinsic manganese content in 
astrocytes and microglia was 50-70 ppb, which is about 30-50 times higher than that of 
PC-12 cells at baseline (measured at 0 µM MnCl2). The intrinsic manganese 
concentrations of glial cells measured in this work are in agreement with previous studies 
[38,39]. The high intrinsic Mn
2+
 concentration in glial cells indicates that Mn
2+
 is an 
important element for the function of glial cells.  
 
2.3.3. MRI Signal Enhancement and Enhanced Volume Measurements  
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At Day 1 after LPS/PBS injections, signal enhancement was found only in 2 mice in each 
group.  Signal enhancement at Day 1 was negligible as compared to Day 7, and was not 
significantly different between the LPS + MnCl2 and PBS + MnCl2 groups (Data not 
shown). At Day 7 after LPS injection, T1-wt images of the LPS + MnCl2 group showed 
strong signal enhancement around the injection line compared to both the surrounding 
tissue and the corresponding region in the contralateral hemisphere. The T1-wt image of a 
Day 7 LPS + MnCl2 mouse was shown in Fig. 2.3.a in three orthogonal planes: coronal 
(upper left), sagittal (upper right) and axial (bottom left). The areas around the injection 
line were encased by red boxes and shown in magnified windows in Fig. 2.3.a. The signal 
enhancement in this area was robust. The T1-wt image of a PBS + MnCl2 mouse was 
shown in Fig. 2.3.b. The PBS injected mice showed minimal enhancement compared to 
the LPS injected mice. The enhancement ratios calculated in the PBS + MnCl2 and LPS + 
MnCl2 groups are shown in Fig. 2.3.c. Statistical analysis showed significantly higher 
signal enhancement ratio in the LPS + MnCl2 group as compared to the PBS + MnCl2 
group, p < 0.01. Similarly as shown in Fig. 2.3.d, enhanced tissue volumes (after 
normalization by injection depths) were significantly larger in the LPS + MnCl2 group 
than in the PBS + MnCl2 group, p < 0.001. There was no obvious signal enhancement in 




At Day 1 after LPS/PBS injection, no reactive astrocytes were found, and only microglia 
detected by Iba-1 were observed in LPS injected mice around the injection line.  A brain 
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slice of a LPS + MnCl2 mouse at Day 1 is shown in Fig. 2.4.a. The Iba-1 staining on a 
region around the injection line (red box) is shown in a magnified (20X) window. As 
described in the preceding paragraph, no significant MEMRI signal enhancement was 
observed in these mice (data not shown). Both astrocytic and microglial reactivity were 
detected at Day 7 in LPS injected mice. The top row in Fig. 2.4.b shows a brain slice of a 
LPS + MnCl2 mouse at Day 7. The GFAP and Iba-1 staining on a region around the 
injection line are shown in magnified (20x) windows. It can be seen that a large number 
of activated astrocytes were detected by GFAP, and activated microglia by Iba-1, in this 
region. A brain slice of a PBS + MnCl2 mouse is shown in the 2
nd
 row in Fig. 2.4.b. The 
areas stained by GFAP and Iba-1 in the region about the injection line (red box) were 
much smaller compared to the LPS + MnCl2 mouse. In quantitative analysis, at Day 7, 
the astrocytic reactivity represented by GFAP expression (p < 0.01) and microglial 
reactivity by Iba-1 expression (p < 0.05) were significantly higher in the LPS + MnCl2 
group than in the PBS + MnCl2 group (Fig. 2.4.c). Immunofluorescence labeling for 
neuronal markers (SYN and MAP2) showed no significant difference in neuronal loss 
between LPS + MnCl2 and PBS + MnCl2 groups around the injection lines (data not 
shown).  
Fig. 2.5.a shows that the correlation between astrocyte and microglial reactivity is 
significant (Pearson’s correlation coefficient, r = 0.62, p < 0.05) in the LPS + MnCl2 
group at Day 7. More interesting is that, at Day 7 in the LPS + MnCl2 group, there was a 
significant correlation between astrocytic reactivity and enhanced tissue volume 
calculated from MEMRI data (Pearson’s correlation coefficient, r = 0.66, p < 0.05) as 
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shown in Fig. 2.5.b. No correlation was found between microglial reactivity and 

























2+ concentration in PC-12 cells co-cultured with astrocytes plotted against 
cytokine treatment level (IFN-γ/TNF-α, ng/ml) at 2 hours (Left) and 15 hours (Right) of 
MnCl2 incubation. (b) Mn
2+
 concentration in PC-12 cells co-cultured with microglia 
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Figure. 2.3. T1-wt images and enhancement quantification. (a) T1-wt image of a PBS + 
MnCl2
 
mouse. The image was shown in sagittal, coronal and axial directions (counter-
clockwise starting from upper right). Areas around the injection line were encased by red 
boxes and shown in magnified windows. (b) T1-wt image of a LPS + MnCl2
 
mouse. (c) 
T1-wt image of a LPS only (no MnCl2 injection) mouse. No obvious signal enhancement 
was observed in the mice injected with only LPS but not MnCl2. (d) Enhancement 
measurements. The LPS + MnCl2 group showed significantly higher signal enhancement 
than the PBS + MnCl2 group (p<0.01). (e) Enhanced volume. Enhanced volumes 
(normalized by dividing it by respective Injection depths). The LPS + MnCl2 group 
















































Figure. 2.4. Immunohistology. (a) A brain section of a LPS + MnCl2 mouse at Day 1 
after LPS injection. The reactive microglia by Iba-1 in the regions encased in red boxes 
about the injection line are shown at 20x. (b) A brain section of a LPS + MnCl2 mouse 
(top row) and of a PBS + MnCl2 mouse (2
nd
 row). The reactive astrocytes by GFAP and 
microglia by Iba-1 in the regions encased in red boxes around the injection line are 
shown at 20x. (c) Glial reactivity quantification. Astrocytic and microglial reactivity 
represented by GFAP and IBa-1 expressions (Intensity/µm
2
) were significantly higher in 


































Figure. 2.5. Correlation comparisons. (a) Correlation between astrocytic and microglial 
reactivity (r = 0.62, p < 0.05). (b) Correlation between astrocytic reactivity and enhanced 








Intrinsic manganese content in neurons is low compared to glial cells, and neuronal 
manganese uptake is partly dependent on the availability of extrinsic manganese. Here 
we investigate the effect of glial reaction on glial and neuronal manganese uptake. The 
results suggest that inflammatory cytokine induced astrocytic activation [40]  stimulates 
Mn
2+ 
uptake of neurons, and that this uptake is proportional to the level of activation. On 
the other hand, microglial reaction has no direct effect in stimulating neuronal Mn
2+
 
uptake, and intensive microglial reaction may even suppress uptake.  
The intrinsic manganese content in astrocytes and microglia is much higher than 
in PC-12 cells as shown in this study and others [38,39]. The high intrinsic Mn
2+
 
concentration in glial cells indicates that Mn
2+
 is an important element for the function of 
these cells. Studies have found that activity of several enzymes in the central nervous 
system is Mn
2+
 dependent, such as superoxide dismutase, ATPase, and glutamine 
synthase [37].  No significant exogenous Mn
2+
 uptake by glial cells was observed in this 
study at any extracellular MnCl2 concentration or glial activation level or time.  
The in vivo imaging study was designed to reveal the effects of microglial and 
astrocytic reactions on MEMRI signal enhancement. The imaging times of Day 1 and 
Day 7 were chosen because, after one day of LPS injection, microglial reaction is well 
defined, and astrocytic reaction generally takes place after three-four days, and becomes 
well established around seven days. 
The in vivo study has clearly demonstrated the co-localization and strong 
correlation between reactive astrocytes and MEMRI signal enhancement. By 
incorporating the in vitro finding that reactive astrocytes stimulate neuronal manganese 
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uptake rather than absorb manganese themselves, we are confident to conclude that the 
MEMRI signal enhancement resulted from the elevated manganese uptake in neurons 
stimulated by astrocytic reaction. 
In GFAP stained brain slices, we also found activated astrocytes in regions remote 
from the injection line in the LPS + Mn
2+
 mice. However the number of the activated 
astrocytes in these regions was small. The neuronal Mn
2+
 uptake caused by these 
astrocytes was not detected in MRI due to the limited sensitivity. 
Several groups have studied the relationship between MEMRI signal 
enhancement and glial reaction in a range of animal models of human disease, including 
but not limited to, cathepsin D deficiency [26], epilepsy [8], ischemia [14,22,27]and 
prenatal X-ray exposure [9]. However, results have been varied. Some studies showed 
elevated MEMRI signal enhancement co-localized with activated microglia [26] or both 
activated microglia and astrocytes [14,22,27]. However the study of prenatal X-ray 
exposure [9] found negative correlation between brain tissue longitudinal relaxivity (R1) 
and reactive astrocytes. Because R1 determines MEMRI signal intensity, this study 
suggested that astrocytic reaction suppressed signal enhancement. Another study of 
epilepsy [8] found no correlation between MEMRI signal change and astrocytic reaction. 
The inconsistent results from these studies could be due to the variety of disease models 
used. In these diseases, a variety of pathobiological events occur in addition to glial 
reaction, such as cell swelling and necrosis [14,22,27], apoptosis [26], and hippocampal 
mossy fiber spouting [8]. These events can impair neurons that could either stimulate or 
suppress neuronal Mn
2+
 uptake, causing inconsistent MEMRI signal enhancement. One 
particular study [24] using rats, found strong positive correlation between MEMRI signal 
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enhancement and astrocytic reaction in a stroke model, and proposed that the signal 
enhancement is caused by Mn
2+
 accumulation in reactive astrocytes through voltage-
gated Ca
2+
 channels. However, this study did not investigate the neuronal reaction to glial 
activation, and thus cannot exclude the contribution of elevated Mn
2+
 uptake by reactive 
neurons to signal enhancement. 
Astrocytes react rapidly to various neurodegenerative insults. Reactive astrocytes 
protect neurons by secluding the injury site from the rest of the CNS area, and secreting 
multiple neurotrophic factors to aid neuronal survival. However, the astrocytic processes 
have been implicated in the pathogenesis of a variety of neurodegenerative diseases, 
including but not limited to, Alzheimer’s disease, Parkinson’s disease, HIV-associated 
neurocognitive disorders, acute traumatic brain injury, and inflammatory demyelinating 
diseases. It is believed that rapid and severe astrocytic reaction initiates or augments 
inflammatory response by secreting various pro-inflammatory molecules leading to 
neuronal death and brain injury [40]. 
Monitoring glial-neuronal interactions dynamically using noninvasive imaging 
technologies is a unique and powerful method, which can be used to understand the 
pathobiology of neurodegenerative diseases, provide diagnosis and prognosis, and aid in 
the development of therapeutic methods. MRI is a noninvasive imaging technology 
providing high spatial resolution, excellent soft tissue contrast and real-time 
measurements. Because Mn
2+
 crosses the brain-blood barrier and enters neurons through 
voltage-gated calcium channels [41], MEMRI has proven to be a powerful tool to study 
neuronal viability, activation and impairment. The results in this study show the potential 
to use MEMRI monitoring of glial-neuronal interactions in normal and abnormal 
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conditions. Our immunohistological results showed no significant neuronal death caused 
by LPS injection at the times when MEMRI was performed. In the future we plan to 
extend the study to later stages at which neuronal death induced by glial reaction occurs. 
We expect to see decreased MEMRI signal enhancement due to the neuronal death as 
shown in several previous studies [10,11,13]. Therefore a longitudinal MEMRI study 
showing neuronal excitation by astrocytic reaction and neuronal death later provides 
valuable information of the progression of pathobiology.  
In conclusion, we demonstrated that astrocytic reaction induces elevated neuronal 
Mn
2+
 uptake that results in MEMRI signal enhancement. This study demonstrates that 
MEMRI can be used not only to monitor neuronal vitality and activity but also to monitor 
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CHAPTER - 3 
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) 















HIV-1-associated neurocognitive disorders (HAND) is a clinical disorder that reflects the 
cognitive, behavioral and motor dysfunctions associated with progressive viral infection 
[1]. HAND reflects a spectrum of clinical abnormalities that include asymptomatic 
neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIV-
associated dementia (HAD) [2]. Although antiretroviral therapy (ART) has significantly 
decreased the HAD incidence and prevalence, ANI and MND are seen in half of infected 
patients [3] and as such continues to be a significant quality of life complication of 
HIV/AIDS [4,5]. Despite advances in the understanding HIV neuropathobiology, disease 
diagnosis is made by exclusion of co-morbid conditions such as drug abuse, 
neurodegenerative and psychiatric disorders, opportunistic infections and malignancies 
[6]. Moreover, levels of viral replication and cognitive impairment are not always linked 
nor do they provide clear relationships between neuropathology and cognitive function 
[4]. It is possible that diagnostic clarity could be provided through imaging biomarkers. 
In attempts to detail HIV-associated neuropathology, our laboratories pioneered 
the development of murine models of virus-associated brain disease [7]. Specifically, we 
show that humanized mice reconstituted with CD34+ human hematopoietic stem cells 
reflect the consequences of viral infection and consequent immune deterioration in its 
human host [8-11]. In this model, human progenitor cells are transplanted into genetically 
modified immunodeficient NOD/scid-IL-2Rγc
null 
(NSG) mice [12]. Such mice support 
persistent  HIV-1  infection  leading  to  behavioral  and  motor impairments paralleling  
Reproduced with permission from Bade AN, Gorantla S, Dash PK, Makarov E, Sajja BR, Poluektova LY, 
Luo J, Gendelman HE, Boska MD, Liu Y; Manganese-Enhanced Magnetic Resonance Imaging Reflects 





neuronal and glial responses [13]. Our recent works demonstrated that brain imaging such 
as proton magnetic resonance spectroscopy (
1
H MRS) and diffusion tensor imaging 
(DTI) can uncover the neuropathological consequences of chronic HIV-1 infection in 
these mice [8,13].  
A significant advantage for manganese-enhanced magnetic resonance imaging 
(MEMRI) over other magnetic resonance imaging (MRI) modalities rests in the ability to 
directly map voltage-gated calcium channel activity through manganese ions (Mn
2+
) 
neuronal accumulation. As Mn
2+
 is a calcium (Ca
2+
) analogue, it can enter neurons by 
voltage-gated Ca
2+
 channels[14] and can be moved anterograde by axonal transport and 
microtubule assembly [15,16]. Mn
2+
 is an excellent T1 shortening contrast agent affording 
relatively high spatial resolution and signal-to-noise ratio within reasonable scanning 
time [17,18]. Administration of Mn
2+
 generates enhanced signal intensity on T1-wt 
images. The signal enhancement is associated with neuronal activities. MEMRI can 
assess neuronal well-being for anatomical, integrative, functional and axonal transport 
activities of nerve cells and their connections [14,19]. Herein, we demonstrate that 
MEMRI facilitates precise noninvasive high spatial resolution (100 μm
3
 isotropic) 
determinations of brain regions of HIV-1 incited neuroinflammation and neuronal injury 
in NOD/scid-IL-2Rγc
null 
humanized mice. Correlations between immunocytochemical 
measures of brain disease and MEMRI signal enhancement are operative.  
 
3.2. Materials and Methods 





(NSG) mice were bred under specific-pathogen-free conditions in 
accordance with the ethical guidelines at the University of Nebraska Medical center 
(UNMC), Omaha, Nebraska. Human cord blood obtained with parental written informed 
consent from healthy full-term newborns (Department of Gynecology and Obstetrics, 
UNMC) was utilized for CD34+ cells isolation using immune-magnetic beads according 
to the manufacturer's instructions (CD34+ selection kit; Miltenyi Biotec Inc., Auburn, 
CA). Numbers and purity of human CD34+ cells were evaluated by fluorescence-
activated cell sorting (FACS). Cells were either frozen or immediately transplanted into 
newborn mice at 10
5
/mouse intrahepatically (i.h.) in 20 μl phosphate-buffered saline 
(PBS) using a 30-gauge needle. Newborn mice received human cells from single donors. 
On the day of birth, newborn mice were irradiated at 1 Gy using a C9 cobalt 60 source 
(Picker Corporation, Cleveland, OH). Starting from 22 weeks after reconstitution, HIV-1 
virus was intraperitoneally (i.p.) injected at 10
4
 TCID50 into mice. Humanized mice 
without infection served as controls. Number of human cells and the level of engraftment 
were analyzed by flow cytometry. In the study, all protocols related to animal 
experiments were approved by the Institutional Animal Care and Use Committee 
(IACUC), UNMC University and met the requirements of the UNMC University ethical 
guidelines, which are set forth by the National Institutes of Health.  
 
3.2.2.Viral load  
The automated COBAS Amplicor System V1.5 (Roche Molecular Diagnostics, Basel, 
Switzerland) was used to measure the peripheral level of viral RNA copies/ml. Mouse 
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plasma (20 µl) was used to dilute with 480 µl of sterile normal human plasma for the 
assay. The baseline detection of assay after dilution is 1250 viral RNA copies/ml.  
 
3.2.3. Flow cytometry  
Peripheral blood leukocytes, spleen and bone marrow cell suspensions were examined for 
anti-human-CD45, CD3, CD4 and CD8 markers. Flow cytometry on peripheral blood 
leukocytes was done every other week from the point of infection. At the end of study, 
flow cytometry was done for spleen and bone marrow as well. Mouse peripheral blood 
samples were collected from submandibular vein (cheek bleed) by using lancets 
(MEDIpoint, Inc., Mineola, NY) in EDTA coated tubes. Antibodies and isotype controls 
(BD Phar-Mingen, San Diego, CA) were used to stain cells. Staining was analyzed by 
using FACSDiva (BD Immunocytometry Systems, Mountain View, CA). Percentages of 
total gated lymphocytes were expressed as results.  
 
3.2.4. Immunohistology 
At 16 weeks, mice were euthanized immediately after imaging and brains were collected. 
Brain tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin. 
Five μm thick brain tissue sections were labeled with mouse monoclonal antibodies for 
HLA-DQ/DP/DR (1:100, Dako, Carpinteria, CA), HIV-1 p24 (1:10, Dako), c-Fos (1:50, 
Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonal antibodies for glial 
fibrillary acidic protein (GFAP) (1:1000, Dako), ionized calcium binding adaptor 
molecule -1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA), Caspase3 (1:10, EMD 
Millipore, Billerica, MA). The polymer-based HRP-conjugated anti-mouse and anti-
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rabbit Dako EnVision systems were used as secondary detection reagents, and 3,3’-
diaminbenzidine (DAB, Dako) was used as a chromogen. All paraffin-embedded sections 
were counterstained with Mayer's hematoxylin. Deletion of primary antibodies served as 
controls. Images were captured with a 100×, 40× and 20× objectives using Nuance EX 
multispectral imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, 
Melville, NY).  
For immunofluorescence labeling, brain sections were treated with the paired 
combination of primary antibodies mouse anti-synaptophysin (SYN) (1:1000, EMD 
Millipore), and rabbit anti-microtubule-associated protein 2 (MAP2) (1:500, EMD 
Millipore), mouse anti-neurofilament (NFs) (1:200, Dako) and rabbit anti-GFAP (1:1000, 
Dako); additionally, brain sections were treated alone with rabbit anti-Iba-1(1:500). 
Primary antibodies were labeled with secondary anti-mouse and anti-rabbit antibodies 
conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and nuclei 
were labeled with DAPI (4,6-diamidino-2-phenylindole). Slides were cover-slipped with 
ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA). Slides were stored at −20 °C 
after drying for 24 hours at room temperature. Images were captured at wavelengths 
encompassing the emission spectra of the probes, with a 40× objective by Nuance EX 
multispectral imaging system fixed to a Nikon Eclipse E800 and image analysis software 
(Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) was used for 
quantification of SYN, MAP2, NF and GFAP expression. Area-weighted average 
fluorescence intensity was calculated in the region of interest (ROI) by dividing the total 




. Images were 
also captured with LSM 710 microscope using a 40X oil lens (Carl Zeiss Microscopy, 
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LLC, NY, USA). Expression of cFos was scored (out of 10) by two investigators using 
20× objective in blinded manner. Findings were compared to animals that were not 
manipulated (score 0). Student’s t-tests were performed to compare immunohistological 
results of the HIV-1 infected animals with controls. 
 
3.2.5. MEMRI 
MnCl2·4H2O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl (Hospira, 
Lake forest, IL) to make 50 mM MnCl2 solution. MnCl2 solution was administrated i.p. 
with the dose of 60 mg/kg consecutively four times at 24 hour intervals before MRI. 
After the injection, the mouse was observed daily to detect the side effects of MnCl2. 
MRI data were acquired 24 hours after the last MnCl2 administration on Bruker 
Bioscan 7 Tesla/21 cm small animal scanner (Bruker, Billerica, MA) operating 
Paravision 5.1 with a 72 mm volume resonator and a 4-channel phased array coil. Mice 
were anesthetized by inhalation of isoflurane in 100% oxygen and maintained 40-80 
breaths/minute. Mice were scanned using T1 mapping sequence (fast spin echo with 
variable repetition time (TR) from 0.4 s to 10 s, 12 slices, slice thickness = 0.5 mm, in-
plane resolution = 0.1 × 0.1 mm
2
) and T1-wt MRI (FLASH, TR = 20 ms, flip angle = 20
o
, 
3D isotropic resolution = 0.1 × 0.1 × 0.1 mm
3
). After MRI, the mice were euthanized and 
tissues were removed for immunohistological study. The same scan was also performed 
before the MnCl2 administration, and the acquired image was used as baseline data for 
the calculation of signal enhancement. 
 
3.2.6. MRI data pre-processing 
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To reduce the influence of the inhomogeneous signal reception on the T1-wt images by 
the phased array surface coil, N3 field inhomogeneity correction [20] was first performed 
on each image using MIPAV (CIT, NIH). The brain volumes in the T1-wt images were 
extracted using an in-house Matlab program [21] based on the level sets method. The 
brain images were then registered to a MEMRI-based NSG mouse brain atlas developed 
in our laboratories using affine transformation first, and then nonlinear transformation 
(DiffeoMap, John Hopkins University, Baltimore, MD).  
To calculate Mn
2+
 induced T1-wt signal enhancement, the MRI system variations 
between the baselines and post MnCl2 injection scans need to be minimized. This is 
achieved by calibrating the baseline and post Mn
2+
 injection T1-wt images using T1 
values. A detailed description of the MEMRI enhancement calculation and T1-wt image 
calibration are described in the MEMRI signal enhancement and tissue manganese 
concentration part of the methods and material section of this chapter. The T1 maps were 
first generated using an in-house Interactive Data Language (IDL) version 8.2 (Exelis 
Visual Information Solutions, Boulder, Colorado) program from the data acquired by T1 
mapping sequence. ROIs were then placed on relatively uniform tissue regions including 
frontal cortex and caudate on T1 maps and T1-wt images. The baseline and post Mn
2+
 


















). The baseline T1-wt image (Sbl) was then calibrated 
using the calibration factor C : Sbl
C
 = Sbl × C.  
 




In this study, MEMRI enhancement is defined as (SMn – Sbl)/SMn, where Sbl and SMn are 
the baseline (bl) and manganese enhanced (Mn) signal, respectively. The spoiled FLASH 
(Fast Low Angle SHot) sequence was used to acquire T1-wt images in this study. The 




where M0 is the spin density, TR and TE are repetition and echo time, respectively. α is 
the flip angle. Therefore, the baseline and manganese enhanced signal are 
 
  (2), 
 
and 
  (3). 
 
The ratio of the manganese enhanced and baseline signals is 
 
  (4). 
 
T2 reduction caused by manganese administration is much less pronounced than T1 
reduction. A previous study showed that in rat cortex, the T2 reduction is about 10% at 24 
hours after MnCl2 injection, while T1 reduces approximately 30% (Chuang KH et al., 
Magnetic Resonance in Medicine, 2009, doi: 10.1002/mrm.21962, PMID:19353652). TE 
is also relatively short as well (=3 ms) in this study. Therefore Eqn (5) can be simplified 
as 
 
  (5) 
 
Recall the Taylor expansion: 
 




Replace x with  in Eqn (6): 
 
,  (7), 
 
and since TR (= 20 ms) / T1 (> 800 ms in most regions after manganese administration) is 
small, the second and higher order terms in Eqn (7) can be ignored, that is, 
. Applying this equation in Eqn (5) and after skipping several 
steps, Eqn (5) can be further simplified: 
 
  (8). 
 
The third terms in both numerator and denominator are at the second order, and thus can 
be dropped similarly to in Eqn (7): 
 
  (9), 
 
where R1 is the relaxitivity, and R1 = 1/T1. Eqn (9) means that the ratio of the signals 
acquired before and after manganese administration is equal to the ratio of relaxivities. 




) of manganese, and 
[Mn] is the manganese concentration in mM, Eqn (9) can be rewritten as 
 
  (10). 
 
Replacing 1 with Sbl/Sbl and subtracting one from each side: 
 
  (11). 
 
From Eqn (11), we can see the tissue manganese concentration [Mn] is proportional to 




MRI scanner system calibration: 
 
System settings such as RF coil, analogue-to-digital converter, and environment temperature can 
change in the post-manganese administration imaging session from the pre-administration 
session. The variation can be minimized by calibrating the system using relaxation times 
measured before and after manganese administration. If we assume that the effect of the system 
variation is a constant C (calibration factor) and set system parameter of the post-manganese 
session as 1, then the acquired baseline signal is Sacq = CSbl. From Eqn (9),  
 
  (12). 
  
T1bl and T1Mn were measured using a fast spin echo sequence with variable TR in this study. Using 
C from Eqn (12), Sbl can be calculated: Sbl = Sacq / C. 
 
3.2.8. MEMRI enhancement analysis 
The Mn
2+





pixel-by-pixel comparison was first performed between the HIV-1 infected mice and the 
control group using Student’s t-test, followed by a brain region specific analysis. Using 
the MEMRI-based brain atlas, the T1-wt signal enhancement on 41 brain regions/sub-
regions was calculated. The student’s t-test was performed to exam the significance of 
enhancement change in each HIV-1 infected brain region compared to the control group. 
The association between MRI signal changes, plasma viral load, T-cells and 
immunohistological results in HIV mice was examined using Pearson product-moment 
correlation. The association between enhancement and quantified GFAP, Iba-1, MAP2, 
NF and SYN staining was studied on the CA1, CA3 and DG brain regions. Time course 
of infection that included measures of the plasma viral load at the time of animal sacrifice 
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(16 WPI), its rate of change (slope) over time, and change in maximum and end time 
viral levels were measured. These parameters tested over time were correlated with MRI 
signal enhancements. The T-cell parameters that were measured over time included 
blood, spleen and bone marrow CD4 and CD8 positive T cell numbers.   
 
3.2.9. Brain structure volumetric analysis 
In the MRI data pre-processing, the brain images were registered to the MEMRI-based 
brain atlas. The 41 brain regions were identified on each brain image. The brain images 
were transferred back to their original spaces employing the inverse of the transformation 
matrices calculated for registration. The volumes of the regions were calculated in the 
original spaces. Student’s t-tests were performed to compare the volumes of the HIV-1 
infected animals with controls. 
 
3.2.10. Detection of Mn
2+
 toxicity 
Animals were observed daily after each i.p. MnCl2 injection and 24 hours after the 
injection. If tremor or convulsion (the signs of manganese overdose) persisted longer than 
3 minutes or lethargy observed at 24 hours, mice were euthanized. 
 
3.3. Results  
3.3.1. HIV-1 Infection of humanized mice 
Humanized mice (n = 8) were infected with the HIV-1ADA at 22 weeks of age (Fig. 3.1.a). 
Viral and immune parameters were assessed then compared against controls (uninfected 
humanized mice, n = 7). Flow cytometry was performed at 2, 4, 7, 10, 13 and 16 weeks 
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post infection (WPI) to determine reconstitution of peripheral human immune cells 
(CD45, CD3, CD4, CD8). The temporal changes of CD4+ and CD8+
 
T cells in infected 
humanized mice are shown in Fig. 3.1.b. The steady CD4+ T cells decline and 
concomitant increases in CD8+ T cells were readily seen in HIV-1 infected mice. Control 
uninfected animals showed no changes in T cell numbers throughout the study period 
(Fig. 3.1.b). Plasma viral RNA copies/ml (viral load, VL) measures were performed at 2, 
7, 16 WPI (Fig. 3.1.c). These VL values peaked at the 2
nd
 week after HIV-1 infection and 
were sustained throughout the experimental observation period.  
 
3.3.2. Leukocyte brain infiltration 
Brain infiltration of human cells including those HIV-1 infected were assessed by 
immunohistochemical assays. At 16 WPI, brain sections at 5 µm thickness were stained 
for human HLA-DR and HIV-1p24. Human HLA-DR+ cells infiltrated the brains of 
infected and control mice were seen in the meninges and perivascular spaces (Fig. 3.1.d). 
Few HIV-1p24+ human cells were observed in these regions of infected mice (Fig. 3.1.e). 
Glial responses were assessed by glial fibrillary acidic protein (GFAP, astrocyte) and 
ionized calcium binding adaptor molecule-1 (Iba-1, microglia) staining. Cortical areas 
with hypertrophic astrocytes and morphological features of activated microglia were 
readily observed (Fig. 3.1.f). Such activated glial morphologies were not seen in control 
animals.  
 
3.3.3. MEMRI  
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To track neuropathology induced by continuous HIV-1 infection, MEMRI was performed 
at 16 WPI (Fig. 3.1.a). The averaged MEMRI image of the control mice is shown on 
coronal brain slices as an anatomical reference in the left column of Figure 3.2.a. 
Positions of the coronal slices are depicted using a sagittal slice (top of the left column). 
Standard tissue signal enhancement induced by Mn
2+
 was readily seen within the 
olfactory bulb, cerebral cortex, hippocampus, and cerebellum [19]. The color-coded 
average enhancement maps of the control and HIV-1 infected mouse brains are illustrated 
in the second and third columns of Figure 3.2.a, respectively. The enhancement 
represented the signal change induced by Mn
2+
 normalized to the MRI signal of pre-Mn
2+
 
administration. MEMRI enhancement changes were observed throughout the brain in 
HIV-1 infected animals compared to controls (Fig. 3.2.a). Statistically significant 
increases in the MEMRI enhancement are shown by pixels with p < 0.05 (the first 
column in Fig. 3.2.b). These p values are color-coded and overlaid on the averaged 
MEMRI slices. Using the MEMRI-based mouse brain atlas, 41 brain regions/sub-regions 
were identified for each humanized mouse. A list of regions on the brain atlas can be 
found in chapter 4 (Table 4.1). The MEMRI enhancement was compared between each 
brain region of control and HIV-1 infected mouse. The regions with p values less than 
0.05 from such comparisons are shown in the second column in Figure 3.2.b and 
illustrated with identical color-coding as in the first column. The brain regions with 
significantly increased signal enhancement (p < 0.05) are also included within Table 3.1. 
Three-dimensional images of brain regions with significant enhancement increase are 
illustrated in Figure 3.2.c. The brain regions showing trends of enhancement increase are 
listed in Table 3.2. Morphological and volumetric changes were assessed in virus-
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infected animals by the MEMRI mouse brain atlas. Whole brain and regional volumes in 
the HIV-1 infected mice were comparable to control animals (data not shown). The 
toxicity of Mn
2+
 was considered. Mice were observed daily after i.p. MnCl2 injections. 





 induced toxic signs and symptoms were observed during the study. 
 
3.3.4. Immunohistology 
Immunohistochemistry was subsequently performed on CA1, CA3 and the dentate gyrus 
(DG) regions of the hippocampus at study termination, 16 WPI (Fig. 3.1.a). Brain 
sections were stained for GFAP, Iba-1, cFos (neuronal activation), synaptophysin (SYN, 
synaptic vesicle protein), and neurofilament (NF, neuronal cytoskeleton protein). 
Fluorescence intensity for these antigens was expressed as intensity/µm
2
. Activated 
morphologies were observed as defined by increased cell body size and process 
formations for both astrocytes and microglia in virus-infected animals (Fig. 3.3.a and 
3.3.b). The presence of activated astrocytes and microglia are known to be linked to 
virus-induced inflammation [22,23]. Neuronal activation (cFos expression) was 
substantially higher in brain regions with gliosis and specifically in the hippocampus; 
indicating increased neuronal excitation during inflammation (Fig. 3.3.c, Fig. 3.5). 
Irregularly shaped and decreased SYN expression was seen in the CA3 region of infected 
animals and reflected synaptic injury (Fig. 3.3.d). Reduction in NF fibers was also 
observed at CA3 region in infected animals (Fig. 3.3.e). NF and SYN expression 
demonstrates neuronal injury after glial inflammation. Co-localized MEMRI 
enhancement in infected animals was compared to controls and confirmed the sensitivity 
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of the MEMRI in reflecting glial and neuronal histochemical and morphological changes 
(Fig. 3.3.f).  
Quantitative immunohistochemistry was used to compare neuropathology 
between control and HIV-1 infected mice and its association with MEMRI regional 
enhancements. In CA1 region, GFAP and Iba-1 expression were significantly higher in 
infected animals than controls (GFAP, p = 0.041; Iba-1, p = 0.018); whereas, SYN and 
NF expression were not different amongst the groups (Fig. 3.4.a). Gliosis with no 
evidence of neuronal injury in CA1 paralleled significant MEMRI signal enhancement 
increase in infected animals compared to controls (p = 0.047) (Fig. 3.4.a). In the CA3 
region, GFAP expression was higher (p = 0.038), and SYN and NF expression lower 
(SYN, p = 0.027; NF, p = 0.005); whereas, Iba-1 signals were not changed by viral 
infection (Fig 3.4.b). With a combination of astrocyte responses and neuronal injury, 
MEMRI signal remained similar between infected and control animals (Fig. 3.4.b). 
GFAP expression was higher (GFAP, p = 0.042) and Iba-1 increased but not significantly 
(Iba-1, p = 0.083) in the DG region of infected animals; whereas SYN and NF signals 
were not changed (Fig. 3.4.c). MEMRI enhancement in this region was increased in 
infected animals (p = 0.045) (Fig. 3.4.c). The quantitative analyses taken together, 
demonstrate that activated glia and neurons (increased cFos staining) during 
inflammation induced the increase in MEMRI signal in the CA1 and DG brain regions. 
However, the enhancement increase was offset by neuronal injury (reduced SYN and NF) 
in the CA3 brain region. Microtubule associated protein (MAP2) staining was not 
changed in the infected animals. Evidence for neuronal apoptosis determined by anti-
caspase3 staining was not observed in infected mice (data not shown). 
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We next investigated if glial activation and MEMRI signal enhancements were 
correlated one with the other. In the CA1 and DG, correlations between GFAP expression 
and MEMRI signal increase were seen (CA1, r = 0.86, p = 0.007; DG, r = 0.92, p = 
0.001). Linkages between gliosis and MEMRI enhancement demonstrated that Mn
2+ 
uptake and accumulation increases in neurons affected by inflammation. This was 
associated with astrocyte responses and the MEMRI signals [24]. Next we measured 
relationships between the degree of brain injuries and VL in blood. The average brain 
MEMRI enhancement alteration was linked, in measure, to the peripheral VL difference 
of at 16 weeks and maximum values (defined as viral load dynamics; r = 0.714, p = 
0.071). This result suggested that the greater the viral load drop during the course of 
infection, the smaller the MEMRI enhancement change. MEMRI enhancement was not 





Figure 3.1. (a) The time course of human CD34+ cell reconstitution, HIV-1 infection, 
MRI, MnCl2 injections and histopathology. (b) Results from flow cytometric analyses of 
human CD4+ and CD8+ cells in peripheral blood of control mice (left) and infected mice 
(right). (c) Average HIV-1 RNAs (copies/ml) in peripheral blood of infected mice (n = 
8). (d and e) Infiltration of human activated cells detected by HLA-DR (indicated by 
arrows, left, 20×) and HIV-1+ cells (detected by p24 antigen) in meninges, parenchyma 
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and perivascular spaces (positive cells indicated by arrows, right, 100×) into the brain of 
infected mice at 16 WPI. (f) Brain sections of control and infected mice stained by GFAP 
for astrocyte (left, 40×) and by Iba-1 for microglial (right, 40×). Activated glial cell 






































































Figure 3.2. Comparison of MEMRI enhancement between HIV-1 infected animals and 
controls. (a) MEMRI enhancement maps. The first column (from left) shows coronal 
slices of the averaged MEMRI of control mice as an anatomical reference. The sagittal 
slice (upper left) shows respective coronal positions (red lines). The second column 
shows the average enhancement in control mice on the coronal slices. The third column 
represents the average enhancement of HIV-1 infected mice. The color bar for the 
enhancement maps is at the top of the figure. Dark blue color (0%) means no change in 
enhancement from Mn
2+
 compared to pre-injection signal intensity. Dark red color 
represents 120% signal increase compared to pre-injection. Increase in MEMRI 
enhancement can be seen throughout the brain of infected animals than controls. (b) 
Statistical comparison of MEMRI enhancement between control and HIV-1 infected 
animals. The left column shows the pixels with significant enhancement difference (p < 
0.05) overlaid onto the averaged brain image. The color bar of p values is at the right. 
Dark blue color represents p = 0.05 and dark red color represents the value of 0.00. The 
right column shows significantly altered brain regions of infected mice using the same 
color scale. (c) Brain regions with significant enhancement changes demonstrated in 3-D. 
(1) Averaged brain image. (2) Right hemisphere of the averaged brain. Internal brain 
regions can be seen on the middle of sagittal section. (1 and 2) are to provide anatomical 
references for the demonstration of regions with significant enhancement changes. (3) 
Sub-cortical regions including CA1_CA3_SUB (red) and CP (green). (4) Sub-cortical 
regions including DG-mo (red), AMY (orange), PALc (green), and GP (yellow). (5) 
Brain stem regions including TH (red), EPI (green), SN (blue) and PRT (purple). (6) 
PAG (blue), IC (yellow), SN (red) and PRT (purple). (7) Olfactory regions including 
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MOB (red), AOB (green), AON (blue) and PIR (yellow). (8) cc (red) and CBXmo (blue). 


































CA1_CA2_SUB: Field CA1 + Field CA2 + Subiculum of Hippocampus Formation, DG-
mo: Dentate gyrus_molecular layer, CP: Caudoputamen, AMY: Amygdala, GP: Globus 
pallidus, PALc: Pallidum caudal region, TH: Thalamus, EPI: Epithalamus, P: Pons, PAG: 
Periaqueductal gray, IC: Inferior colliculus, SN: Substantia nigra, RMB: Rest of midbrain 
, PRT: Pretectal region, MOBgl: Main olfactory bulb glomerular layer, AOB: Accessory 
olfactory bulb, PIR: Olfactory piriform area, AON: Anterior olfactory nucleus, CBXmo: 
Cerebellar cortex molecular layer, cc: corpus callosum, (p < 0.05) (p: t test p value)  
 
  Brain regions p 
  CA1_CA2_SUB 0.047 
 
DG-mo 0.046 
Sub-cortical CP 0.039 
region AMY 0.048 
  GP 0.028 
  PALc 0.047 





Brain stem PAG 0.022 
region IC 0.01 
  SN 0.041 
  RMB 0.033 
  PRT 0.043 
  MOBgl 0.021 
Olfactory AOB 0.012 
 region PIR 0.046 
  AON 0.036 
Cerebellar CBXmo 0.031 
region     

















Isocortex, STRv: Striatum ventral region, LSX: Lateral septal complex, MS: Medial 
septal nucleus, DG-(po+sg): Dentate gyrus_(polymorph layer + granular layer), HY: 
Hypothalamus, MY: Medulla, CBXgr: Cerebellar granular layer, CBwm: Cerebellar 
white matter, FN: Fastigial nucleus 
 
  Brain regions p 
Isocortex Isocortex 0.06 
  STRv 0.065 
Sub-cortical LSX 0.053 
region MS 0.055 
  DG-(po+sg) 0.071 
Brain stem HY 0.074 
region MY 0.051 
Cerebellar CBXgr 0.053 
region CBwm 0.07 
  FN 0.071 
    Table 3.2. Brain regions that showed trend of signal enhancement increase  




Figure 3.3. Immunohistology of the hippocampus sub-regions including CA1, CA3 and 
DG (40×). Representative brain sections of control and HIV-1 infected mice stained for 
GFAP (astrocyte), Iba-1 (microglia), cFos (neuronal activation), SYN (synaptic vesicle 
protein), NF (neuronal cytoskeleton protein) and co-localized MEMRI slices are 
presented. (a, b and c) Increase in GFAP, Iba-1 and cFos expression was observed in 
infected animals compared to controls in all three regions of hippocampus. (d and e) In 
CA3 region, SYN and NF expression was decreased (indicated by an oval and arrows, 
respectively) of infected animals compare to controls, but not in CA1 or DG. (f) Altered 




Figure 3.4. Association of immunohistology with MEMRI. (a) Quantitative analysis 
showed significant increase in GFAP, Iba-1, and MEMRI enhancement on CA1 region of 
HIV-1 infected animals compared to controls. (b) CA3 region showed significantly 
increased GFAP, significantly decreased SYN as well as NF, and no change in MEMRI 
signal in infected animals compared to controls. (c) DG region showed significantly 
increased GFAP, a trend of increased Iba-1, and significantly increased MEMRI 
enhancement in infected animals compared to controls. Data are expressed as mean 















Figure 3.5. cFos expression at hippocampus region. HIV-1 infection caused significant 
increase in cFos expression compared to control. Data are expressed as mean SEM.  (*: 














Figure 3.6. The mechanism of MEMRI in the detection of neuropathology in HIV-1 
infected humanized mice. (a) Human immune system reconstitution (humanization) in 
NSG mouse. Human CD34+ stem cells (HSC) isolated from umbilical cord blood were 
injected intrahepatically into one day old irradiated pups. The injected HSC reach mouse 
lymphoid organs including bone marrow and develop into broad range of cell lineages. A 
mature human immune system develops in the NOD/scid-IL-2Rγc
null 
(NSG) mice. (b) 
Humanized mouse brain. Human cells (macrophages, yellow color) are majorly observed 
at meninges and perivascular spaces in humanized mouse brain. Mouse cells (resting glia 
and neurons) are showed in green colors. (c) HIV-1 infected humanized mouse brain. 
Infected human macrophages carry HIV-1 (green) into the brain and release pro-
inflammatory cytokines, chemokines viral proteins, that leads to activated glia (red) 
followed by neuronal excitation (blue) and injury (gray). (d) HIV-1 induced 
neuropathology, Mn
2+ 
accumulation and associated MEMRI signal enhancement. Mn
2+ 
(blue and pink circle) enters brain through choroid plexus. Being Ca
2+ 
analog, it enters 




 is transported anterogradely by 
microtubule assembly. Once Mn
2+ 
is released, it is taken up by post-synaptic neurons. 
Mn
2+
 accumulation increases in activated neurons during inflammation resulting in 
MEMRI signal enhancement increase (stronger purple outer glow compared to control). 
Whereas, Mn
2+
 uptake and transportation are reduced in injured neurons and thus 







Humanized mouse model (NSG/CD34+) of HIV/AIDS can, in part, mirror human HIV-1 
associated neuropathology [8,9,13] and was used successfully to test ART efficacy [25]. 
Peripheral VL and human CD4+ T-cell decline are hallmarks of HIV-1 infection in 
humans which are reflected in these humanized mice. Moreover, a metabolic 
encephalopathy caused by viral infection resulting in micro- and astro- gliosis, myelin 
pallor, excitotoxicity and neuronal injury is also seen in both humans and infected mice 
[8,9,13,22]. Such spectrums of pathologies make the humanized mice a relevant model for 
study. In the present study, altered MEMRI brain signal is seen in HIV-1 infected mice 
that serve to assess the complexities of neuropathology that underlie HAND’s clinical 
manifestations. Although, MEMRI was used previously to study a range of 
neurodegenerative disease models [26-29], this is the first report of its use to study effect 
of HIV-1 on humanized mice brain function and anatomy with improved analytical 
method. 
MEMRI enhancement for HIV-1 infection is linked to reactive astrocytes and 
activated neurons. The cellular basis of the enhancement change was investigated in a 
previous study and interpreted as elevated neuronal Mn
2+
 uptake and accumulation 
stimulated by astrocyte activation [24]. The associations between MEMRI signal with 
reactive astrocytes and neuronal responses was previously observed [24,29,30]. We 
previously showed that activated glia do not accumulate excessive Mn
2+
 but stimulate 
neuronal Mn
2+
 uptake [24]. Thus, MEMRI can be used to monitor virus-associated 
neuronal excitotoxicity that occurs as a consequence of neuroinflammation. In the CA3 
region, both inflammation and neuronal injury (synaptic and axonal injury) were 
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operative in the infected animals. This is consistent with the fact that neuronal damage 
caused by HIV-1 infection begins with synaptic damage, compromised dendrite arbor, 
then neuronal death occurs as a consequence of persistent infection and immune 
deterioration [31]. Interestingly, in CA3 region, we did not observe MEMRI signal 
increase as in CA1 and DG. Indeed, damaged neurons likely influence reduction in 
neuronal Mn
2+ 
accumulation. The voxel size of MEMRI was 100 µm
3
, which contains a 
large number of cells. The MEMRI enhancement of each voxel resulted from the 
combining effects of activated and injured neurons. Simply, the MEMRI signal 
enhancement induced by activated neurons was likely offset by signal decrease in injured 
cells. Increasing spatial resolution can partially solve the problem as excited and injured 
neurons may be differentiated. Additionally, performing MEMRI and 
immunohistological analysis at multiple time points after the infection may also establish 
accurate associations between signal enhancements and neuronal injury.  
The cellular mechanisms underlying MEMRI enhancement is summarized in 
Figure 3.6. Humanized mice permanently carry human blood cells, and these populate 
brain primarily at meninges and perivascular spaces. After HIV-1 infection, infected 
human monocyte-macrophages carry HIV-1 into the brain and release pro-inflammatory 
cytokines, chemokines, viral proteins. This leads to activation of murine glia followed by 
neuronal excitotoxicity and injury, which in turn reflects the brain injuries seen as a 
consequence of chronic HIV-1 infection. Systemically administrated Mn
2+
 enters the 
brain through choroid plexus. As a Ca
2+
 analog, it enters neurons through voltage gated 
Ca
2+
 channels and is transported anterogradely by microtubule assembly. Once Mn
2+
 is 
released, it is taken up by post-synaptic neurons. Reactive astrocytes that arise as a 
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consequence of HIV-1 induced neuroinflammation first cause elevated neuronal Mn
2+
 
uptake resulting in increased MEMRI signal enhancement. Neuroinflammation then 
results in neuronal injury with consequently suppressed MEMRI signal.  
In our parallel works, behavioral tests were used to show memory loss and 
cognitive dysfunction in these infected mice [13]. As the hippocampus plays an important 
role in memory and cognition, the glial activation and neuronal injury in this brain region 
detected in this study may contribute to such behavioral abnormalities. Aside from the 
hippocampus, the brain regions that show MEMRI signal enhancement following HIV-1 
infection include sub-regions of the olfactory system, sub-cortical, brain stem and 
cerebellar regions. These findings suggest that infected mice can suffer motor and 
autonomic nervous system dysfunction because of cerebellar and brain stem damage. As 
different parts of the brain have variable vulnerabilities to HIV-1 infection [32,33], the 
current study provides a unique opportunity for unbiased mapping of region specific 
neuropathology.  
The MEMRI results are supported by the DTI measures in our parallel study [13]. 
This study showed altered DTI parameters on hippocampal regions in HIV infected 
humanized mice, and association between the DTI parameters and quantitative histology. 
In infected human and nonhuman primates, abnormal DTI was found in the frontal and 
parietal white matter, putamen, and corpus callosum indicating neuroinflammation and 
axonal/myelin injury [34,35]. In parallel, inflammation metabolic abnormalities were 
detected by MRS in the basal ganglia, cerebrum, caudate, thalamus, and hippocampus 
[34-36]. We acknowledge that a direct comparison of the brain imaging findings in 
humans and nonhuman primates with mice is difficult due to differences in anatomy, 
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physiology, and neurochemistry. Our results are consistent with these human and non-
human primate studies.  
It is likely that abnormalities seen in these animals were not primarily a result of 
active viral replication in nervous system, but largely a consequence of replication in 
blood and peripheral lymphoid organs. Until now, studies have shown that peripheral 
blood nadir CD4+ T-cells count and viral DNA are systemic predictors of HIV-1 induced 
neurocognitive disorders [3,37,38]. However, we did see a trend towards correlation 
between MEMRI signal enhancement alteration and a plasma viral load measure, which 
is the difference between the maximum value and at 16 WPI. A parallel study found that 
viral levels correlated with cortical lactate [13]. The same study also found the correlation 
or the trend of correlation between cortical and dentate gyrus DTI parameters and viral 
load. Their study along with ours suggested that peripheral viral load might be associated 
with the neuropathology reflected by imaging in HIV-1 infected humanized mice. Such a 
sensitivity of the brain to peripheral events in these animals indicates a dynamic 
pathogenic process; where HIV-1 infected blood cells enter into the brain and cause 
disease [39].  
We now demonstrate that MEMRI is a sensitive biomarker of HIV-1-induced 
neuropathology. However, when inflammation and neuronal impairment occur 
simultaneously, both increase and decrease in MEMRI signal can be observed. In order to 
improve the specificity of imaging on neuropathology, it is reasonable to combine 
MEMRI with other imaging modalities. For example, another study showed that the 
cerebral cortex is a primary region of damage in infected mice as demonstrated by MRS 
and DTI [13]. Combining MEMRI with MRS and DTI can positively determine 
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neuroinflammation (increased MEMRI enhancement and increase in myoinositol), and 
may help to detect neuronal impairment (reduced MEMRI enhancement, loss of N-
acetylaspartate and creatine, reduced diffusivity, and fractional anisotropy). This package 
of imaging modalities will greatly enhance our ability for non-invasive assessment of 
HIV-1 induced neuropathology. In addition to assessment of neuronal Mn
2+
 uptake, 
MEMRI can provide precise anatomical details. To this end, we applied a MEMRI-based 
NSG mouse brain atlas to assess brain morphology to reveal abnormalities associated 
with HIV-1 infection in an animal study. As we expected, we did not find changes in total 
brain and sub-structural volumes with altered MEMRI enhancement. This suggests that 
neuronal death is limited in infected animals. MEMRI successfully provided both insights 
into neuronal function and the measurements of brain anatomy.  
The toxicity of Mn
2+
 was minimized by a carefully designed MnCl2 
administration. We have used a fractionated administration scheme first proposed by [40]. 
In this scheme, MnCl2 solution was injected daily through i.p. with a small dose for 
certain days (usually 4-8 days), 4 days for our study. Mice were observed daily after the 
injection and we did not observe any Mn
2+
 induced toxic clinical signs and symptoms. In 
toto, we demonstrate that MEMRI can be developed as a biomarker of virus-associated 
neuropathology. With a thorough understanding of the relationships between MEMRI 
and neuropathology, monitoring the efficacy of brain therapeutics can be realized for 
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CHAPTER - 4 
Generation of a Manganese-Enhanced Magnetic Resonance 
Imaging (MEMRI)-based NOD/scid-IL-2Rγc
null














4.1. Introduction  
Advancements in genetic engineering enabled wide spread use of transgenic mice for 
biomedical research. These mice are extensively used in studies of cell, tissue and 
organism growth, differentiation and disease. Immune deficiency induced by affecting 
the integrity of the adaptive immune system in NOD/scid-IL-2Rγc
null
 (NSG) mice 
permitted the efficient and sustained engraftment of human immunocytes in mice [1,2]. 
As a result, these mice are used for studies of a broad range of human diseases covering 
the disciplines of oncology, hematology, infectious disease and regenerative medicine. In 
particular, our laboratories and others have pursued investigation of human 
immunodeficiency virus type one (HIV-1) pathobiology including the studies of viral 
reservoirs and direct tissue injuries including the lung and the central nervous system 
(CNS) [3-5].  
Apropos to studies of end organ diseases associated with HIV-1 infection, 
magnetic resonance imaging (MRI) has provided critical insights into the mechanisms of 
virus-induced damage as well as repair following antiretroviral therapy (ART). We posit 
that such investigations can be substantively improved if specific mouse atlases are 
generated. Such an atlas could permit broad longitudinal investigation of brain 
morphology under conditions that mimic aspects of human neurologic disease. 
Specifically, brain parcellation can automate analyses of structure-wise MRI based 
metrics (e.g., T1 and T2 relaxation times, diffusion tensor imaging (DTI) measures, 
metabolites concentrations, pharmacokinetics and pharmacodynamics (PK and PD), and  
Reproduced with permission from Sajja BR, Bade AN, Zhou B, Uberti MG, Gorantla S, Gendelman HE,  
Boska MD, Liu Y; Generation and Disease Model Relevance of a Manganese Enhanced Magnetic 
Resonance Imaging-Based NOD/scid-IL-2Rγc
null
 Mouse Brain Atlas; J Neuroimmune Pharmacol. 2015, 




drug biodistribution of magnetically labeled cells and nanomaterials). These works would 
serve to complement and extend analyses of morphological aberrations seen during 
progressive infection. Such measures could also be harnessed as biomarkers of disease as 
well as to determine drug efficacy.  
Mouse brain atlases were developed by others [6-13]. Such works were heralded 
through the need to integrate gene expression with neuroanatomical data and now 
available as an online public resource [14]. Indeed, recent studies have focused on 
generating developmental and functional brain atlases [11]. The realization of multi-
dimensional (multi-modality and/or multi-parametric) data is notable [10,15]. 
Acquisition of high resolution data with high signal-to-noise ratios (SNR) 
involves long MRI scanning times that are difficult in a live mouse. To overcome such 
difficulties, most researchers have performed ex vivo imaging on brain-in-skull or fixed 
brains and created mouse brain atlases. However, tissue deformations that are common 
and are linked to the type and duration of brain preparation and fixation methods may 
affect the atlases generated. Thus, in vivo MRI data based atlases can help improving 
accuracy of brain atlases constructed and can be used for longitudinal analyses of 
individual mice. In vivo atlases on C57BL/6J mouse brain were generated before by 
others [16,17]. We wished to take this idea a step further in sensitivity through the use of 
manganese enhanced MRI (MEMRI). Administration of MnCl2 shortens T1 relaxation 
times in most brain structures, improving signal to noise per unit time and providing 
excellent contrast between many brain substructures including hippocampus, olfactory 
bulbs, cerebellum, and cerebral cortical layers as noticed in the present study and 
previous studies [18,19]. This allows T1-weighted brain MRI at high field strength to be 
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used to acquire high resolution in vivo images while providing enhanced contrast for 
brain structure identifications. As high-resolution 3D MRI show significant 
neuroanatomical differences between mouse strains [20], generation of a brain atlas on 
the same genetic background as used for a disease model serves to enhance accuracy of 
brain tissue segmentation on MRI. To these ends, the current study developed a 3D in 
vivo MEMRI atlas of NSG mouse.  
 
4.2. Materials and methods 
4.2.1. Experimental animals 
Nineteen NSG mice (male, weight = 28.5 ± 2.4 grams, age ~ 1 year) from a University of 
Nebraska Medical Center (UNMC) breeding colony were used in study. Animals were 
maintained in sterile microisolator cages under pathogen-free conditions in accordance 
with ethical for care of laboratory animals at UNMC set forth by the National Institutes 
of Health. All procedures were approved by the University’s Institutional Animal Care 
and Use Committee. Seven human CD34
+
 hematopoietic stem cells (HSC) reconstituted 
(humanized) NSG mice (male, weight = 22.1 ± 5.3 grams, age ~ 1 year) were scanned 
using MEMRI to study brain morphology. Additional 6 NSG mice (male, weight = 30.6 
± 2.9 grams, age ~ 1.5 years) were included in the study for whole brain T2-weighted 
MRI data acquisition without MnCl2 administration. 
 
4.2.2. Human CD34+ HSC reconstitution (humanization) of NSG mice 
CD34-NSG mice were generated as described in [5]. Human CD34
+
 HSC were obtained 
from cord blood (Department of Gynecology and Obstetrics, UNMC) and enriched to 
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high purity by magnetic bead selection (Miltenyi Biotech Inc., Auburn, CA). The purity 
of CD34
+
 cells was >90% by flow cytometry. Cells were transplanted into newborn mice 
irradiated at 1Gy using a C9 cobalt 60 source (Picker Corporation). CD34
+
 cells were 
injected intrahepatically at 10
5
 cells/mouse in 20 µl of PBS using a 30 gauge needle. The 
levels of engraftment and number of human cells in peripheral blood were analyzed by 
flow cytometry (Dash et al., 2011).   
  
4.2.3. MnCl2 administration 
MnCl2.4H2O (Sigma-Aldrich, St Louis, MO) was added to saline (0.9% w/v of NaCl 
solution) to make 120 mM MnCl2 solution. MnCl2 was administered at a dose of 125 
mg/kg bodyweight using intravenous (i.v.) injections through the tail vein. MnCl2 was 
injected using a syringe pump (Harvard Apparatus, MA) at the rate of 125 µL/hour. The 
dosing scheme was designed based on our experience in MEMRI and several previous 
studies [19,21-24]. Mice were placed on an electrically heated tail vein injection platform 
(Braintree Scientific, MA), and were anesthetized by inhalation of isoflurane in 100% 
oxygen. Breathing rate, cardiac rate and blood oxygen saturation were continuously 
monitored. Anesthesia level was varied from 0.3% to 1.5% isoflurane to maintain the 
breathing rate between 40-100 breaths per minute. Immediately after the injection, the 
mouse was placed on a heating pad in the cage, and its behavior was observed up to four 
hours to detect the side effects of MnCl2. The animal was then returned to the animal 
facility and scanned 24 hours later. 
  
4.2.4. MRI data acquisition 
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MRI of the 19 NSG mice used for atlas generation were scanned 24 hours after MnCl2 
administration on Bruker Biospec 70/20 (Bruker, Billerica, MA) operating Paravision 4.0 
with a custom-built 18 mm birdcage volume coil. The humanized mice that were used to 
study the effect of humanization on brain volume were scanned using the same MRI 
scanner operating Paravision 5.1. An 82 mm actively decoupled volume resonator was 
used for signal transmission and a four-channel phase array coil was used for reception.  
 Mice were anesthetized by inhalation of isoflurane in 100% oxygen and 
maintained 40-80 breaths/minute. Three-dimensional T1-weighted data were acquired 
using a Rapid Acquisition with Relaxation Enhancement (RARE) sequence with the 
following parameters: Repetition time (TR) = 400 ms, Effective echo time (TEeff) = 7.2 
ms, RARE factor = 4, number of averages = 1, image matrix = 176 × 128 × 128 with 100 
µm isotropic pixel size, total scan time = 27 min, anterior-posterior as the readout 
direction. MRI data were acquired from both normal and humanized mice. Three-
dimensional T2-weighted MRI were obtained from six NSG mice without MnCl2 
administration using the same scanning parameters as for 3D T1-weighted data except: 
TR/TEeff = 1500/36 ms, RARE factor = 8, number of averages = 1, total scan time = 1h 
55m. 
 
4.2.5. Population averaged MRI mouse brain 
All MR brain images were manually brain extracted by separating brain from extracranial 
tissue using Analyze 10.0v software (www.analyzedirect.com). All brains were registered 
to median size brain in the group using rigid image registration. Population average brain 
was created by averaging all registered individual brain images. Then all individual brain 
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images were iteratively (3 times) affine registered to population average brain and 
average was updated at each iteration [6]. Finally, nonlinear registration of individual 
brain images to the average was performed using Large Deformation Diffeomorphic 
Metric Mapping (LDDMM) to align differences. To minimize the interpolation errors, 
transformation matrices from individual registrations were combined and applied in one 
step to each original MRI to generate the final average. All the registration procedures 
were performed using Diffeomap 1.6v as implemented in DTIStudio software 
(www.mristudio.org). The final step was to sharpen the boundaries between anatomic 
features (enhanced brain) by applying the Laplacian as: 
𝑔(𝑥, 𝑦) = 𝑓(𝑥, 𝑦) − ∇2𝑓(𝑥, 𝑦) 
where g(x, y) and f(x, y) represent enhanced and input images respectively, and 
2
 
represents the Laplacian operator.  
 
4.2.6. Structures delineation and labeling 
Paxinos atlas (Paxinos and Franklin, 2001) and Allen brain digital atlas [14] 
(http://mouse.brain-map.org/) were followed as reference for identifying and naming 
different structures on the averaged MEMRI brain images. Amira

 5.21v VSG software 
(www.amira.com) was used for generating colored labels of brain structures. A three 




4.3.1. Brain structures labeling 
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Representative slices from three orthogonal cross-sections of the population averaged 
MRI are shown in the first column of Fig. 4.1. The second displays the same slices with 
Laplacian edge enhancement. Improved contrast between structures is realized. The third 
column shows the manually labeled structures using Amira software.  Significant image 
contrast seen is due to MnCl2 and allowed the identification and delineation of 41 brain 
structures from the cerebrum (CH), brain stem (BS), cerebellum (CB), fiber tracts (FB), 
and ventricular systems (VS). All the identified structures’ names are listed in Table 4.1. 
To the best of our knowledge this is the highest number of structures identified on in vivo 














Figure 4.1. Columns: First: Three orthogonal planes of population average MRI. Second: 
Edge enhancement of images in first column. Third: Identified structures on these planes: 
 AMY,  ac,  AON,   CA1_CA2_SUB,  CA3,   CP,  Central AMYN, 
 CBXgr,  CBXmo,  CBwm,  AQ,  cc,  Isocortex,   DG-mo,  DG-
(po+sg),  DN,  EPI,  RFB,  FN,  GP,  HY,  IC,  IP,  LSX,  
VL,  MY,  AOB,  MOBgl,  MOBgr,  PIR,  opt,  PALc,  MS,  
PAG,  P,  PRT,  RMB,  SN,  TH,  V3,  V4,  STRv (Note: 
Structures  ac, AQ, DN, RFB, FN, IP, V3, and V4 are not presented in the third column 
















Table 4.1. List of brain regions labeled on MEMRI brain atlas.                       
Region Structure 
CH: Cerebrum  





MOBgl: Main olfactory bulb, glomerular layer 
MOBgr: Main olfactory bulb, granule layer 
AOB: Accessory olfactory bulb 
AON: Anterior olfactory nucleus 





CA1_CA2_SUB: Field CA1 + Field CA2 + Subiculum 
CA3: field CA3 of hippocampus 
DG-mo: Dentate gyrus_molecular layer 
DG-(po+sg): Dentate gyrus_(polymorph layer + granular 
layer) 
  
 STR: Striatum 
CP: Caudoputamen 
STRv: Striatum ventral region 
LSX: Lateral septal complex 
   
 PAL: Pallidum 
PALc: Pallidium, caudal region 
GP: Globus pallidus 
MS: Medial septal nucleus 
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 AMY: Amygdala AMY: Amygdala 
FB: Fiber tracts 
 
 
cc: corpus callosum  
opt: optic tract  
ac: anterior commissure 
RFB: Rest of fiber tracts 
BS: Brain stem  
 TH: Thalamus 
EPI: Epithalamus 
HY: Hypothalamus 
IC: Inferior colliculus 
PAG: Periaqueductal gray 
PRT: Pretectal region 
SN: Substantia nigra 




CB: Cerebellum  
 
CBXmo: Cerebellar cortex, molecular layer 
CBXgr: Cerebellar cortex, granular layer 
CBwm: Cerebellar white matter 
FN: Fastigial nucleus 
IP: Interpose nucleus 



















VS: Ventricular system  
 









We have developed a 3D in vivo MEMRI brain atlas for NSG mice containing 41 sub 
regions. We acknowledge that although this is not the first mouse brain atlas made, it is 
the sole one constructed by MEMRI for NSG mice analyses. Majority of previous such 
constructions were made on fixed or post-mortem in situ brains [7,9,10]. However, such 
prior works may not provide accurate assessment of in vivo volumetric and geometrical 
changes amongst brain regions [16,25]. Indeed, fixation protocols cause alterations in 
analyses for brain morphology even when MRI data with high resolution and SNR are 
employed. To this end, the present in vivo MEMRI brain atlas allows longitudinal 
quantitative morphological studies.  
There are some advantages of the present approach. First, due to MnCl2 ability to 
selectively reduce local T1 relaxation times, the MEMRI provided increased contrast to 
noise ratio. Second, boundaries between brain structures are enhanced by Laplace 
Transform image processing. Third, specific molecular and granular layers in the brain 
regions such as the olfactory bulb and cerebellum were identified (Fig. 4.1.). Through 
such an approach, 41 structures on averaged in vivo MRI were delineated and then 
labeled. This is a significant improvement from prior 3D in vivo MRI atlases that enabled 
only half of the MEMRI-identified brain structures to be processed [16,17]. The 
developed atlas is made available to researchers through Neuroimaging Informatics Tools 
and Resources Clearinghouse (NITRC) website   
(https://www.nitrc.org/projects/memribrainatlas/).  




An in vivo MEMRI-based atlas was generated for brains of NSG mice. Forty-one brain 
structures were identified to provide a coordinate system for spatial normalization. The 
atlas provides a database for studies of brain morphology, metabolomics, MR metrics, 
disease pathobiology, and drug pharmacokinetics in a range of infectious, inflammatory 
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CHAPTER - 5 
Potential of N-acetylated-para-aminosalicylic Acid to 
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)-enhanced MRI (MEMRI) is a powerful imaging tool to measure 
rodent neural structure, function and linked pathways [1-3]. It is facilitated by Mn
2+
 entry 
into neurons that occurs through calcium (Ca
2+
) channels. Here, Mn
2+
 ions accumulate in 
neurons and are transported along axons. Such ion trafficking reflects neuronal function 
and networks [1-5]. Mn
2+
 is an excellent T1 shortening paramagnetic contrast agent 
inducing signal enhancement on T1-weighted (T1-wt) MRI. The retention of Mn
2+
 in 
brain is prolonged with a half-life (t1/2) of 51 to 74 days [5]. Such ion retention allows 
studies of brain function performed on non-restrained awake rodents [6-10]. In this 
context, Mn
2+
 administration, sensory stimulation and/or behavioral tests are performed 
outside the MRI scanner and prior to imaging tests. Studies have shown that brain 
activities that took place days before imaging tests could be detected using appropriate 
Mn
2+
 administration schemes such as implanted osmotic pump infusion [9,10]. The long 
Mn
2+ 
brain retention time also enables the monitoring of Mn
2+ 
axonal transportation for 
studies evaluating neural pathways[11-13]. MEMRI is also proven a valuable tool in 
neurodegenerative disorder studies using rodents [14-25]. However and despite such 
advantages, its application is limited in the longitudinal follow-up of neurodegenerative 
disorders due to the prolonged washout time of Mn
2+
. During the time span of the studies 
that can be as long as weeks and even months, repeated Mn
2+
 administration is usually 
necessary to keep brain Mn
2+
 concentration consistent among imaging sessions. This 
requires  carefully designed  dosing  if imaging needs to be performed  before the residual  
Reproduced with permission from Bade AN, Zhou B, McMillan J, Narayanasamy P, Veerubhotla R, 
Gendelman HE,  Boska MD, Liu Y; Potential of N-acetylated-para-aminosalicylic acid to accelerate 
manganese enhancement decline for long–term MEMRI in rodent brain; J Neurosci Methods. 2015, Aug 






 from preceding administrations is eliminated. Infusion using commercially 
available osmotic pumps may keep brain Mn
2+
 concentration consistent for up to six 
weeks (Alzet, Cupertino, CA), which is usually not sufficient in time to evaluate the 
progression of neurodegenerative disorders in rodents. Moreover, repeated or continuous 
Mn
2+
 administration can cause secondary toxicities [26]. One solution is to accelerate 
Mn
2+
 brain elimination after each MEMRI tests and as such limit the effect of residual 
Mn
2+
 on the MEMRI evaluation. Accelerated Mn
2+
 washouts may also serve to minimize 
Mn
2+
 toxicity.   
With this in mind, we tested whether N-acetylated-para-aminosalicylic acid 
(AcPAS) could accelerate Mn
2+
 elimination from brain. AcPAS, an N-acetylated 
metabolite of para-aminosalicylic acid (PAS), was previously used to treat human 
manganism, a disorder which parallels several of the clinical features of Parkinson’s 
disease [27]. Treatment of Mn
2+
 intoxication is linked to PAS chelation [28,29]. 
Chelation is the binding of organic compounds and metal ions. The brain distribution, 
metabolism, and time-concentration relationships of PAS and its major metabolite, 
AcPAS, were previously investigated [30,31]. The results demonstrated that AcPAS 
chelates Mn
2+
. AcPAS has higher brain concentration and possesses a longer t1/2 than 
PAS. Herein we demonstrate that AcPAS can be employed to improve the MEMRI utility 
by permitting serial brain measurements in health and disease.   
 
5.2. Materials and Methods 
5.2.1. Study Design 
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C57BL/6 mice were used in this study. Mice were housed in the University of Nebraska 
Medical Center (UNMC) laboratory animal facility according to the American Animal 
Association and Laboratory Animal Care guidance. All procedures were approved by the 
Institutional Animal Care and Use Committee at UNMC. The kinetics of AcPAS in brain 
tissue and plasma was first studied using high-performance liquid chromatography 
(HPLC) using one group of mice. Another group of mice was first administrated MnCl2 
via the intraperitoneal (i.p.) route, followed with PBS (n =3), low dose (n = 3, 100 
mg/kg), medium dose (n = 3, 150 mg/kg) and high dose AcPAS (n = 3, 200 mg/kg) three 
times daily for two weeks. The doses and administration scheme were designed based on 
the previous PK studies of AcPAS [30,31]. MRI was performed one day after the MnCl2 
administration followed by AcPAS/PBS treatment. Two more MRI scans were performed 
at one and weeks of AcPAS/PBS treatment. After the last MRI, the mice were 
immediately euthanized for inductively coupled plasma mass spectrometry (ICP/MS) 
analysis of brain Mn
2+
 concentrations. The timeline of the study design is shown in Fig. 
5.1. Three animals were randomly selected from the above 12 AcPAS/PBS-treated mice 
and were scanned before any drug administration for baseline measurements of MRI and 
ICP/MS. 
 
5.2.2. AcPAS Synthesis 
AcPAS was synthesized by a modified procedure [32]. Briefly, p-aminosalicylic acid 
(0.33 mol), was dissolved in 100 ml of 2 M hydrochloric acid and stirred with sodium 
acetate (0.33 mol) in water at 0° C. The reaction mixture was stirred overnight with 50 ml 
of acetic anhydride at room temperature. The brown precipitate obtained was filtered, 
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washed, dried and dissolved in 0.1M sodium hydroxide then stirred overnight. The 
resulting solution was adjusted to pH 2 with HCl. The product was extracted with ethyl 
acetate (3 × 75 ml) and the extracts were dried over anhydrous sodium sulphate. The 
solid residue was washed with hexane to produce 52 % yield of pure AcPAS. The 
identity of AcPAS was confirmed by NMR with > 99 % purity. 
 
5.2.3. High performance liquid chromatography (HPLC)  
AcPAS (200 mg/kg) was administered to mice (n = 9) by i.p. injection. Plasma was 
collected at 0.5, 1, 2, 6 and 12 hours. Mouse peripheral blood samples (100 µl) were 
collected from submandibular vein (cheek bleed) by using sterile lancets (MEDIpoint, 
Inc., Mineola, NY) in EDTA coated tubes. Plasma was separated by centrifugation of 
blood samples at 1,800 rpm for 8 min at 4°C within 1 h of sample collection and stored at 
-80°C until analysis. Brain tissues (cortex, thalamus, olfactory bulb) of same group of 
mice administered with the same dose of AcPAS were collected at 6, 8 and 12 (n = 3 for 
each time point) hours after administration. AcPAS from plasma and tissues were 
extracted using acetonitrile. AcPAS was quantified by HPLC according to the method of 
Sugamori et al. [33]. Briefly, extracted plasma or brain samples were injected in duplicate 
(20µl) onto a Shimadzu HPLC (Shimadzu Scientific Instruments, Columbia, MD) 
containing a Synergi 4µ Hydro-RP column (4.6 × 150 mm) (Phenomenex, Torrance, CA) 
and extruded using an isocratic mobile phase of 7% acetonitrile/1% acetic acid/0.1% 
triethylamine at a flow rate of 1.6 ml/min. AcPAS were detected at a wavelength of 270 




5.2.4. MnCl2 and AcPAS treatment 
MnCl2·4H2O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl2 (Hospira, 
Lake forest, IL) to make 50 mM MnCl2 solution. MnCl2 solution was delivered i.p. at a 
dose of 60 mg/kg consecutively four times at 24 hour intervals. The fractional 
administration scheme was designed to minimize Mn
2+
 toxicity [34]. After injection, the 
mice were observed daily to monitor potential Mn
2+ 
toxicities. AcPAS injection started 
one day after the MnCl2 administration. AcPAS (1 mg) was mixed with 1 μl DMSO in a 
glass container. More (1 – 2 μl) DMSO was added until the compound was dissolved. 
Physiological saline (0.9% NaCl) was added to dilute the solution to 20 mg/ml AcPAS. 
The solution became a suspension with addition of saline. It was then stored at 4 
o
C. 
Before each injection, the suspension was thoroughly mixed by shaking. AcPAS was 
injected i.p. 3 times per day at eight-hour intervals for two weeks. Before each drug 
injection, the animal was observed for any abnormal changes in behavior, hair coat, facial 
expression, ambulation and body weight. 
 
5.2.5. MRI 
MRI was performed on a Bruker Bioscan 7 Tesla/21 cm MRI (Bruker, Billerica, MA) 
operating Paravision 5.1 with a 82 mm quadrature volume resonator and a 4-channel 
phased array receive coil. Mice were anesthetized by inhalation of isoflurane in 100% 
oxygen and maintained 40-80 breaths/minute. Mice were scanned using T1 mapping (fast 
spin echo with variable TR from 0.4 s to 10 s, TE = 7.0 ms, 12 coronal slices, slice 
thickness = 0.5 mm, in-plane resolution = 0.156 × 0.156 mm
2
, FOV = 20 x 20 mm
2
) and 





, FOV = 19.2 (Left - Right) x 19.2 (Superior - Inferior) x 30.0 (Anterior - Posterior) 
mm
3
, spatial resolution = 0.1 × 0.1 × 0.1 mm
3
).  
To reduce the influence of the inhomogeneous signal reception on the T1W 
images by the phased array surface coil, N3 field inhomogeneity correction [35] was first 
performed on each image using MIPAV (CIT, NIH). The brain volumes in the T1W 
images were extracted using an in-house Matlab program [36] based on the level sets 
method. The brain images were then registered to the MRI-based mouse brain atlas 
downloaded from the Laboratory of Neuro Imaging (LONI) at the University of Southern 
California using affine transformation first, and then nonlinear transformation 
(DiffeoMap, John Hopkins University, Baltimore, MD).  
To use signal changes in high resolution T1W MRI to represent Mn
2+
 
accumulation, signal differences need to be scaled to absolute changes in T1 values. This 
is achieved by calibrating the baseline and post Mn
2+
 injection T1W images using T1 
values. The T1 maps were first generated using an in-house Interactive Data Language 
(IDL) version 8.2 (Exelis Visual Information Solutions, Boulder, Colorado) program 
from the data acquired by T1 mapping sequence. Regions of interest (ROI) were then 
placed on relatively uniform tissue regions including frontal cortex and caudate on T1 
maps and T1W images. The baseline and post Mn
2+
 injection longitudinal relaxivity and 
T1W signal intensity in the ROIs were measured. We assumed that the effect of the 
system variation is a constant C (calibration factor) and set system parameter of the post-





CSbl, where Sbl is the true (calibrated) baseline signal. The calibration factor was 
calculated as C = (Sbl
C





injection longitudinal relaxivities, respectively; SMn is post Mn
2+
 T1W signal intensity. 
The calibration factor was then applied to the baseline T1W image to calculate the true 
baseline image: Sbl = Sbl
C
 / C.  
The Mn
2+
 induced T1W signal enhancement was calculated by: (SMn – Sbl) / Sbl. 
This equation was derived by ignoring the T2* effect in the MRI signal generated using a 
spoiled gradient recalled echo, and replacing the exponential of (-TR/T1) with the first 
two terms of its Taylor expansion. These operations were appropriate as a previous study 
has shown that Mn
2+
 induced T2 change is small compared to T1 reduction [37], and (-
TR/T1) is small (TR = 20 ms and T1 > 800 ms in most brain regions). Using the LONI 
brain atlas, enhancement on brain regions/sub-regions was calculated. A region-by-region 
comparison was performed between AcPAS treated groups and PBS controls using 
Student’s t-test at each time point.  
 
5.2.6. ICP/MS Analyses 
Known weights of thawed brain regions (cortex, thalamus, olfactory bulb), collected from 
the animals were decomposed by wet-ashing in vials with six volumes of concentrated 
nitric acid followed by microwave (MARS, CEM Corp., Matthews, NC) heating at 200 
°C. Total manganese concentrations were determined by ICP-MS (NexION 300Q, 
PerkinElmer, MA, USA).  
 
5.2.7. Statistical Analysis 





5.3.1. AcPAS plasma and brain levels 
AcPAS plasma and brain concentrations are shown in Figure 5.2. AcPAS was reduced in 
concentration at 2 hours from > 400 to < 23 ng/ml in plasma. The reduction reached eight 
ng/ml at 12 hours. AcPAS increased in the cortex, thalamus and olfactory bulbs with time 
after six hours. The highest AcPAS tissue concentration was in olfactory bulbs with less 
drug in the thalamus and cortex (Fig. 5.2). 
 
5.3.2. MRI  
Mn
2+ 
induced enhancement on T1W MRI was seen after 24 hours of MnCl2 injection (Fig 
5.3.A-a). Mn
2+ 
induced signal enhancement on T1W MR images was seen in the 
hippocampus, cerebellum and olfactory bulbs (Fig 5.3.A-a) [3,4]. The MR images one 
week after MnCl2 injection are illustrated in Fig 5.3.A-b with the top panel the PBS and 
bottom high dose AcPAS treated mice. The signal intensity was decreased at 1 week in 
both groups. Compared to PBS controls, decreased signal intensities were seen in AcPAS 
treated mice. This was most notable in the hippocampus and cortex. After 2 weeks of 
treatment, AcPAS treated mice (Fig 5.3.A-c, top panel) showed greater decreased signal 






The enhancement maps are shown in Fig 5.3.B, and quantified region-specific 
enhancement results are listed in Table 1. After 24 hours, Mn
2+ 
induced enhancement is 
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throughout the whole brain (96% enhancement) with the relatively high enhancement on 
olfactory system (Olf, 97%), lateral olfactory tract (lo, 136%), optic chiasm (ox, 98%), 
hippocampus (HIP, 97%), hypothalamus (Hy, 98%), interpeduncular nucleus (IP, 97%), 
and cerebellum (Cb, 96%) regions (Fig 5.3.B-a, 1
st
 column in Table 5.1). The brain 
region abbreviations follow the conventions in the Paxinos and Franklin mouse brain 
atlas. Natural enhancement decline was clearly seen in PBS controls after one week from 
85-136% to 30-62% (Fig 5.3.B-b top panel, 2
nd
 column in Table 5.1). Mice treated with 
low (100 mg/kg) and medium (150 mg/kg) doses did not show significant difference 
compared to PBS controls (data not shown). The enhancement in high dose (200 mg/kg) 
AcPAS treated mice was lower than in PBS animals (Fig 5.3.B-b). The enhancement 
difference was significant (p < 0.05) on substantia nigra (SN), corpus callosum (cc), 
thalamus (Th), hippocampus (HIP) and olfactory bulb (Olf) regions (3
rd
 column in Table 
5.1).  
The enhancement decreased significantly after two weeks in PBS controls to 22-
59% (Fig 5.3.B-c top panel, 4
th
 column in Table 5.1). After two-weeks, medium dose 
(150 mg/kg) AcPAS treated mice showed significantly decreased enhancement compared 
to PBS controls on fornix (f) and optic chiasm (ox) (5
th
 column in Table 5.1). In high 
dose (200 mg/kg) AcPAS treated mice, a number of brain regions showed significantly 
decreased enhancement including the caudate putamen (CPu), basal ganglia (BG) and 
internal capsule (ic) (6
th
 column in Table 5.1). The whole brain enhancement in high dose 
(200 mg/kg) AcPAS treated mice was also significantly less than in PBS controls. The 
brain regions with significantly reduced enhancement in high dose (200 mg/kg) AcPAS 
treated mice are shown in Fig 5.4.  
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Manganese concentrations measured by ICP/MS in mouse brains at 24 hours after 
MnCl2 administration were 183±25.8 parts per billion (ppb) in cortex, 280±29.2 ppb in 
thalamus, 203±14.8 ppb in hippocampus, and 507±164 ppb in olfactory bulbs. The 
concentrations were presented as mean±SEM. The concentrations decreased in PBS 
treated controls after 2 weeks to 61.6±1.45, 71.7±2.96, 57.6±7.61 and 170±21.4 ppb in 
cortex, thalamus, hippocampus and olfactory bulbs, respectively. The concentrations in 
high dose AcPAS treated mice at two weeks were 74.3±9.29, 85.3±22.2, 72.8±26.6, and 
119±19.4 ppb in cortex, thalamus, hippocampus and olfactory bulbs, respectively. No 
significant difference was found between saline controls and AcPAS treated mice (p > 




This study investigated the abilities of AcPAS treatment to affect repeated MEMRI 
measurements of brain structure and function. We demonstrate that, even though AcPAS 
did not lead to accelerated Mn
2+
 brain elimination, it suppressed significantly Mn
2+
-
induced MRI enhancement after about two weeks treatment when using the high dose  
(200mg/kg × 3 daily). Based on these findings, AcPAS has the potential to enable 
repeated MEMRI measurements and minimize Mn
2+
 toxicity. 
AcPAS can be rapidly eliminated from blood within an hour. As soon as six hours 
after the injection, AcPAS has entered the brain and its concentration increased over the 
next six hours. This finding is in agreement with a previous PK study of PAS and AcPAS 
(32). These findings suggested that, to achieve sufficient brain concentrations, AcPAS 
must be administrated by multiple injections over a day or by continuous infusion. 
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Therefore the dosing and administration scheme were designed based on these findings 
and previous PK and PD studies of AcPAS (32). The accelerated Mn
2+
 washout induced 
by AcPAS is different among brain regions. HIP, TH, CPu are among the regions of 
fastest washout. This is in the agreement of a previous study showing high AcPAS 
concentration in these regions [30].  
The ICP/MS data suggested that AcPAS failed to speed the elimination of Mn
2+
. 
However, MRI results showed faster enhancement decline in AcPAS treated mice 
compared to PBS controls at high dose. The discordant results can be explained as 
follows. The chelation of paramagnetic Mn
2+
 by AcPAS limits its interaction with water 
molecules, and thus causes the decrease in Mn
2+
 induced signal enhancement. On the 
other hand, the high tissue affinity and long t1/2 of AcPAS limit the elimination of 
chelated Mn
2+
 from brain. 
The study showed that an average 17% enhancement remains in brain after 2-
week high dose AcPAS treatment. Further experiments are necessary to determine the 
time to complete elimination of enhancement. Nevertheless, AcPAS provides an option 
for serial studies with a shorter time interval compared to the inherent Mn
2+
 washout of 
17-26 weeks [5]. We did not observe any side-effects of AcPAS in the animals. It is quite 
possible that higher dose (> 200 mg/kg) AcPAS treatments would eliminate the 
enhancement more quickly than the highest dose used in this study.  
A more comprehensive study is being planned, in which a second MEMRI 
experiment will be performed after AcPAS treatment to ensure the enhancement 
efficiency still holds, and Mn
2+
 update and retention by neurons are not affected after the 
AcPAS treatment.  The study will prove the feasibility of using AcPAS for repeated 
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MEMRI. We do not expect AcPAS treatment causes brain water relaxivity changes, 
because AcPAS is an organic compound cleared from brain with a half-life of 100-200 
minutes [30], and is diamagnetic. To prove the hypothesis, one more group of mice will 
be added in the planned study that will receive AcPAS treatment and MRI scans but not 
MnCl2 injection. This group is to detect any effect on brain water relaxivity caused by 
AcPAS treatment. 
PAS [4-amino-2-hydroxybenzoic acid (Paser); CAS number, 65-49-6] has been 
well known as an antituberculosis drug since the 1950s [38]. Its side effects on humans 
have been investigated [38]. The toxicity of its tissue metabolite - AcPAS needs to be 
further studied for use in MEMRI. In this study, no abnormal changes in behavior, hair 
coat, facial expression, ambulation and body weight were found in the animals. Even 
though AcPAS does not accelerate the removal of Mn
2+
 from brain, its chelation of Mn
2+
 
is believed to minimize Mn
2+
 toxicity. If AcPAS is to be used in neurological disease 
studies using rodent models, its compatibility with the studies needs to be considered to 
assure its administration will not advertently affecting key physiological/disease-related 
parameters. In conclusion, we showed that, while AcPAS does not eliminate Mn
2+
 from 
brain, it accelerates Mn
2+
 induced enhancement decline in MRI. The results suggested the 
potential to use AcPAS for serial MEMRI measurements of voltage-gated calcium 
channel activity and morphology in rodent brains. In future studies, we will follow the 
animals longer to study the long-term effects of AcPAS on Mn
2+
 elimination and parallel 







Figure 5.1. Study design. Mice were first administrated with MnCl2, followed with PBS 
(n =3), low dose (n = 3, 100 mg/kg), medium dose (n = 3, 150 mg/kg) or high dose 
AcPAS (n = 3, 200 mg/kg) for two weeks. MRI was performed on the mice at one and 
two weeks after MnCl2 administration. After the second MRI, the mice were immediately 












 i.p. injection   





Figure 5.2. AcPAS concentrations measured by HPLC in plasma (blue line) and in the 
brain regions (red lines). The concentrations in plasma were measured in ng/ml (left 
vertical axis), and in brain were measured in ng/mg (right vertical axis). The error bar at 





Figure 5.3. (A) MRI data. (a) Averaged MRI of mice (n = 9) at 24 hours after MnCl2 
administration. (b) Averaged MRI of PBS controls (n = 3, top panel) and high dose 
AcPAS treated mice (n = 3, bottom panel) at one week after MnCl2 administration. (c) 
Averaged MRI of PBS controls (n = 3, top panel) and high dose AcPAS treated mice (n = 
3, bottom panel) at two weeks after MnCl2 administration. (B) Manganese enhancement 






Figure 5.4. Brain regions with significantly less enhancement in mice after one (A) and 
two (B) weeks high dose AcPAS treatment compared to in PBS controls. The regions are 
shown in coronal slices, whose locations are indicated using red lines on the sagittal 




















Table 5.1. Brain regions with significantly decreased enhancement in mice after 1 and 2 
weeks high dose AcPAS treatment compared to in PBS controls. 
Enhancement data are presented as percentage and in Mean ± Standard deviation. 
*
: p < 0.1; 
**








0 week 1 week 2 weeks 




















Cb 96±13 39±7 32±7 28±6 21±3 19±4
*
 
SN 91±12 40±4 30±7
**
 22±8 16±4 12±5
*
 
IP 97±14 50±3 37±11
*
 31±9 24±2 18±7
*
 












Th 89±13 38±4 28±5
**












BG 95±13 42±4 33±8
*
 31±8 21±1 17±6
**
 
HIP 97±13 42±4 33±6
**
 29±8 20±0 17±5
**
 
lo 136±24 62±20 60±11 59±12 45±2 39±9
**
 
Olf 97±13 45±8 31±8
**
 28±5 22±1 20±6
*
 
Cx 95±14 40±8 32±6
*
 29±8 23±0 18±4
*
 
ic 85±16 30±4 24±7 22±6 16±6 13±4
**
 
fr 95±17 38±6 32±4
*
 27±10 23±5 17±6 
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CHAPTER – 6 
















Translational animal models of brain disorders remain essential for thorough 
understanding of the patho-biological mechanisms, as comprehensive research cannot be 
done in controlled and reproducible manner on humans. Research directed at 
morphological, pathophysiological mechanisms and functional activities of the CNS can 
be realized through imaging systems in vivo. A significant literature now demonstrates 
the importance and utility of MRI towards unraveling the complex neural system, healthy 
or diseased. MRI is a non-invasive and versatile imaging tool. It allows longitudinal, 
three-dimentional assessment of tissue anatomy, pathophysiology, function and 
metabolism.  Due to these properties MRI has achieved widespread success in 
experimental neuroscience studies. Yet, there is a room for improvement in MRI 




MEMRI opens the great opportunity to study complex paradigms in freely 
behaving animals. By taking the advantage of chemical and biological properties of Mn
2+
 
in living organisms, MEMRI has been successfully applied in the studies of several 
neurological diseases using animal models, such as stroke, Parkinson’s disease, 
Alzheimer’s disease, epilepsy, and other brain disorders to assess detailed information 
about neuronal activity, morphology and neuronal tracts as well as rate of axonal 
transport. Mn
2+
 is toxic, however, MEMRI revels new patho-biological information that 
might be otherwise difficult to gain. Properly planned administration of Mn
2+
 and close 
monitoring of animals after administration is required to avoid toxicity and pain to 
animals. Although previous studies highlight the potential of MEMRI for brain imaging, 
the limitations still exist concerning the use of Mn
2+
 in living animals. The development 
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of MEMRI applications in neuroscience research are at the beginning level. Therefore, 
development of methods of MEMRI for experimental studies remains essential for 
diagnostic findings as well as development of therapeutic strategies.   
In the first study (Chapter - 2), we investigated role of glia and neurons in 
MEMRI signal enhancement during inflammation. Unlike other contrast agents such as 
gadolinium, iron oxide, and iron platinum Mn
2+
 can provide unique intracellular insights 
about brain pathophysiology. Nonetheless, a critical question that remained poorly 
understood was the brain cells that serve as sources for the MEMRI signal enhancement 
during inflammation. In this study, we investigated MEMRI’s abilities to detect glial 
(astrocyte and microglia) and neuronal activation signals following treatment with known 
inflammatory inducing agents. The idea was to distinguish between gliosis (glial 
activation) and neuronal injury for the MEMRI signal and as such use the agent as a 
marker for neural activity in inflammatory and degenerative disease. This work 





 content was not associated with glial activation. After in vitro 
conformation, we validated our hypothesis in vivo. MEMRI was performed on mice 
injected with lipopolysaccharide by IC route. MEMRI signal enhancement was 
associated with increased neuronal activity. In conclusion, results supported the notion 
that MEMRI reflects neuronal excitotoxicity and impairment that can occur through a 
range of insults that include neuroinflammation and MEMRI signal enhancement in the 
CNS is induced by astrocytic activation by stimulating neuronal Mn
2+
 uptake. 
In the second study (Chapter - 3), we evaluated the efficacy of MEMRI in 
diagnosing the brain pathology in an animal model of neurodegenerative disease, 
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neuroAIDS. Progressive human immunodeficiency viral (HIV) infection commonly leads 
to a constellation of cognitive, motor and behavioral impairments. These are collectively 
termed HIV-associated neurocognitive disorders (HAND). While antiretroviral therapy 
(ART) reduces HAND severity, it does not affect disease prevalence. Despite decades of 
research there remain no biomarkers for HAND and all potential co-morbid conditions 
must first be excluded for a diagnosis to be made. To this end, we now report that 
MEMRI can reflect brain region specific HIV-1-induced neuropathology in chronically 
virus-infected NOD/scid-IL-2Rγc
null 
humanized mice. MEMRI diagnostics mirrors the 
abilities of Mn
2+
 to enter and accumulate in affected neurons during disease. T1 relaxivity 
and its weighted signal intensity are proportional to Mn
2+ 
activities in neurons. In 16-
week virus-infected humanized mice, altered MEMRI signal enhancement was easily 
observed in affected brain regions. These included, but were not limited to, the 
hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, substantia nigra and 
cerebellum. MEMRI signal was coordinated with levels of HIV-1 infection, 
neuroinflammation (astro- and micro- gliosis), and neuronal injury. MEMRI accurately 
demonstrates the complexities of HIV-1 associated neuropathology in rodents that 
reflects, in measure, the clinical manifestations of neuroAIDS as it is seen in a human 
host.  
In the third study (Chapter – 4), our successful collaboration with Dr. Sajja BR 
(Associate Professor, Department of Radiology, UNMC, Omaha, NE) led to generation 
of a MEMRI-based NOD/scid-IL-2Rγc
null
 (NSG) mouse brain atlas. Strain specific mouse 
brain MRI atlases provide coordinate space linked anatomical registration. This allows 
longitudinal quantitative analyses of neuroanatomical volumes and imaging metrics for 
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assessing the role played by aging and disease to the central nervous system. As NSG 
mice allow human cell transplantation to study human disease, these animals are used to 
assess brain morphology. MEMRI improves contrasts amongst brain components and as 
such can greatly help identifying a broad number of structures on MRI. To this end, NSG 
adult mouse brains were imaged in vivo on a 7.0 Tesla MR scanner at an isotropic 
resolution of 100 µm. A population averaged brain of 19 mice was generated using an 
iterative alignment algorithm. MEMRI provided sufficient contrast permitting 41 brain 
structures to be manually labeled. The developed atlas is made available to researchers 
through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website   
(https://www.nitrc.org/projects/memribrainatlas/).  
In the fourth study (Chapter – 5), we evaluated the efficacy of N-acetylated-para-
aminosalicylic acid (AcPAS) to accelerate Mn
2+
 elimination from rodent brain. The brain 
retention of Mn
2+
 is relatively long with a half-life (t1/2) of 51 to 74 days causing a slow 
decline of MRI signal enhancement following Mn
2+
 administration. Such slow decline 
limits using repeated MEMRI to follow the central nervous system longitudinally in 
weeks or months. This is because residual Mn
2+
 from proceeding administrations can 
confound the interpretation of imaging results. To the best of our knowledge, no method 
exists to accelerate the decline of the Mn
2+
 induced MRI enhancement for repeated 
MEMRI tests. We investigated whether AcPAS, a chelator of Mn
2+
, could affect the 
decline of Mn
2+
 induced MRI enhancement in brain thus enabling repeated MEMRI, and 
as a consequence broadens the utility of MEMRI tests. Two-week treatment with AcPAS 
(200 mg/kg/dose × 3 daily) accelerated the decline of Mn
2+
 induced enhancement in 
MRI. (In the whole brain on average the enhancement declined 83% in AcPAS treated 
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mice, while in PBS controls the decline was 73%. We posit that AcPAS could enhance 
MEMRI utility for evaluating brain biology in small animals. Further study needed for 
detailed understanding.  
In general, major disadvantage of MEMRI is the toxicity associated with Mn
2+
, 
which restricted its clinical transformation.  As obtained MEMRI contrast is directly 
related to accumulation of Mn
2+ 
in excitable cells in activity dependent manner, MEMRI 
has been successfully used to study neuronal activation. However, difference in Mn
2+
 
influx and efflux rates (long half-life in brain) or long clearance time allowed to produce 
only static activation maps and do not allow to inform about temporal or rapid changes in 
neuronal activity (Silva et al. 2012). Also, it remains to be investigated whether MEMRI 
detects neuronal deactivation (Silva et al. 2012). We have demonstrated that MEMRI 
visualizes reactive astrogliosis (increase in signal intensity) and neuronal loss (decrease 
in signal intensity; ongoing study in the lab, data not shown in this thesis). But limitation 
is that one of the dominating cellular mechanisms offsets other mechanism to determine 
the MEMRI results. MEMRI is still not sensitive enough to detect gliosis and neuronal 
loss at the same time. Also, threshold level of cellular activity for generating MEMRI 
signal is not studied yet.  
In all the studies of this thesis, we have measured and compared T1 signal 
intensities on three-dimensional (3D) high-resolution (<= 100 μm pixel size) T1-wt 
images for healthy and diseased animals. T1 values were also measured using multi-slice 
MRI with lower in-plane resolution. MRI scanner system variation was then estimated 
using the T1 values and T1-wt signal. The acquired T1-wt images were then calibrated. 
Detailed process of the image calibration is described in chapter - 3 of this thesis. We are 
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now developing a fast T1 mapping sequence to directly measure brain T1 values by a 3D 
high-resolution fashion. This method will provide more accurate results on brain Mn
2+
 
uptake and accumulation. 
There are extensive possibilities for future applications of MEMRI in translational 
neuroscience research. The possibility of longitudinal studies enable the measurement of 
functional changes in CNS after pharmacological interventions as well as therapeutic 
treatment. Integration of MEMRI with multiple imaging modalities will overcome the 
limitations of previous single parametric approach and therefore, will establish a 
comprehensive study to understand neurobiological mechanisms underlying normal and 
abnormal functions.  
 
 
 
 
 
 
